SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/11

20110286915 - Nanocarriers for drug delivery: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate... Agent: The Regents Of The University Of California

20110286916 - Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor... Agent:

20110286918 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.... Agent: Immunomedics, Inc.

20110286917 - Novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described.... Agent:

20110286919 - Conjugates of noscapine and folic acid and their use in treating cancer: The present invention is directed to compounds which are conjugates of two non-toxic natural products, noscapine (and various noscapine analogs) and folic acid (and various folic acid analogs), where the folic acid is conjugated to noscapine or the noscapine analog at the 9-position on the isoquinoline ring on the noscapine... Agent: Emory University

20110286920 - Complex of bifunctional chelating agent and mannosyl human serum albumin: The present invention is about bifunctional chelating agents (BCA) conjugated mannosyl human serum albumin (MSA) and its radioisotope labeled compounds for imaging immune system such as macrophages, Kupffer cells, reticuloendothelial system (RES), and lymphatic system. The present invention comprises BCA-MSA conjugates, their radiolabeled compounds, and kits for radiolabeing. The present... Agent: Snu R&db Foundation

20110286921 - 18f-labelled folates as pet radiotracers: The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.... Agent: Merck & Cie

20110286922 - Imaging and radiotherapy methods: The present invention relates to in vivo imaging and radiotherapeutic methods and agents which target the enzyme aldehyde dehydrogenase (ALDH) and that are suitable for the in vivo imaging of tumours and treatment of cancer.... Agent:

20110286926 - Degradable hydrogel compositions and methods: This invention concerns an in situ biodegradable hydrogel drug delivery system in which the components are assembled in a manner that provides a mechanism for the timed cleavage of a particular amide bond in a covalently linked active agent or of the hydrogel structure.... Agent: Rutgers, The State University Of New Jersey

20110286925 - Embolizing sclerosing hydrogel: A sclerosing embolizing hydrogel comprising from about 0.1% by weight to about 4.0% by weight of chitosan; from about 0.01M to about 1M of hydrochloric acid; from 0% by volume to about 40% by volume of iopamidol; from 0.5% by weight to about 25% by weight of β-glycerophosphate disodium salt;... Agent:

20110286923 - Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases: s

20110286924 - Novel human endogenous retroviral erv3 variant and uses thereof in the diagnosing ovarian cancer: The present invention relates to polynucleotide and polypeptide sequences of a novel human endogenous retroviral ERV3 variant which is differentially expressed in ovarian cancer cells when compared to normal cells. The present invention more particularly relates to the use of these polynucleotide and polypeptide in the diagnosis, prognosis or treatment... Agent: Alethia Biotherapeutics Inc

20110286927 - Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity: In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.... Agent: Cornell University

20110286931 - Cardiac arrhythmia treatment methods and biological pacemaker: Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and... Agent: The Johns Hopkins University

20110286928 - Methods and compositions for inhibition of bcl6 repression: Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods or blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian cell, and methods of treating a mammal with cancer are provided.... Agent:

20110286930 - Methods of identifying modulators of the pp2a b56 beta regulatory subunit: The present invention is based at least in part on the discovery that the PP2A B56 regulatory subunit plays a role in regulating insulin signaling by directly regulating phosphorylation of AKT-I. Accordingly, the present invention features methods of identifying modulators of the PP2A B56 regulatory subunit in assays featuring organisms... Agent: University Of Massachusetts

20110286929 - Multivalent constructs for therapeutic and diagnostic applications: The invention provides compositions and methods for therapeutic and diagnostic applications.... Agent:

20110286937 - Synthetic glycolipid-containing liposome: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the... Agent: Katayama Chemical Industries Co., Ltd.

20110286938 - Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles: Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided.... Agent: The Regents Of The University Of Colorado

20110286935 - Multi-functional nano-device: A universal drug delivery platform for monoclonal antibody-based therapeutics is described. This universal platform resolves the problems of immunogenic response associated with the present monoclonal antibody based therapeutics by providing a multifunctional nano-device which comprises a well defined core/shell nano-structure that can function as a drug delivery platform linked to... Agent: Atrp Solutions, Inc.

20110286936 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent:

20110286934 - Membrane transduction peptides, polynucleotides, and methods: Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human... Agent: Stc. Unm

20110286933 - Monofunctional carbocyanine dyes for in vivo and in vitro imaging: The present invention provides symmetric carbocyanine dyes and dye precursors useful for fluorescence microscopy, and methods of making and using same.... Agent: The General Hospital Corporation

20110286932 - Optical method for the detection of alzheimer's disease: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of... Agent: Cedars-sinai Medical Center

20110286939 - Osteogenic compositions containing a coloring agent: An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near... Agent: Warsaw Orthopedic, Inc.

20110286940 - Composition for the treatment of keratinous fibers comprising at least one fixing polymer and at least one compound of the ceramide type and methods for using the composition: The invention relates to a cosmetic composition for the treatment of keratinous fibres, in particular human hair, comprising at least one anionic, nonionic, amphoteric or zwitterionic fixing polymer and at least one compound of the ceramide type as well as to the method of treatment using this composition.... Agent: L'oreal S.a.

20110286941 - Combination of two material compositions for an oral hygiene product: The present application relates to a combination of two separately stored and jointly used compositions, which are suitable for the combat and the prevention of caries. Thereby, each of the two compositions respectively comprises a fluorine compound. Further, one composition comprises an acidic pH-value, while the other composition comprises a... Agent:

20110286943 - Compositions and methods for providing ultraviolet radiation protection: The present invention provides sunscreen compositions and associated methods. In one aspect, for example, a sunscreen composition can include a cosmetically acceptable carrier and a plurality of nanoparticles dispersed in the carrier with a dispersant. The nanoparticles include at least one sun-block functional group operable to provide UV radiation protection.... Agent:

20110286945 - Compounds, formulations and methods for reducing skin wrinkles, creasing and sagging: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly... Agent: Galderma Laboratories Inc.

20110286944 - Methods and compositions for safe and effective treatment of erythema: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.... Agent: Galderma R&d Inc.

20110286942 - Topical composition comprising a chaotrope: Topical compositions with a chaotrope are described. The compositions can comprise guanidinium chloride or a derivative thereof and an active, and they unexpectedly display rapid active delivery and improved active functionality upon application.... Agent: Conopco, Inc., D/b/a Unilever

20110286946 - Sunscreen compositions containing hydrolyzed jojoba esters for improved water resistance: Sunscreen compositions suitable for topical application are provided. The sunscreen composition includes at least one sunscreen active. Further, the sunscreen composition contains a water resistance agent including hydrolyzed jojoba esters, jojoba esters, and water. The water resistance agent provides for trapping the sunscreen active against the user's skin so that... Agent: International Flora Technologies Ltd.

20110286948 - Bacterial cellulose film and uses thereof: A bacterial cellulose film is provided, including microbial fibers consisting of bacterial cellulose, wherein the microbial fibers are arranged in a density gradient in a direction of the bacterial cellulose film thickness.... Agent: Nympheas International Biomaterial Corp.

20110286950 - Cosmetic compositions of varying viscoelasticity: The present invention is directed to stable cosmetic composition which is waterproof, comfortable and has a unique cushiony/bouncy texture and feel containing: (a) a reaction product of (i) at least one polyamine and (ii) at least one oil soluble high carbon polar modified polymer; (b) water; (c) at least one... Agent: L'oreal S.a.

20110286947 - Method for making up or caring for keratinous substances with noncrosslinked polyrotaxanes: A subject-matter of the invention is a cosmetic method for making up or for the nontherapeutic care of keratinous substances chosen from the nails, skin, lips or eyelashes, the method consisting in: a. depositing on the said keratinous substances at least one layer of at least one first composition comprising... Agent: L'oreal

20110286949 - Stable compositions of varying viscoelasticity: The present invention is directed to cosmetic compositions having an unique texture and feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) optionally, at least one volatile solvent, other than water; (e) at least one non-volatile oil capable of solubilizing the... Agent:

20110286951 - Transfer resistant cosmetic compositions having a unique texture and feel containing at least two polar modified polymers: The present invention also relates to a cosmetic composition comprising: (a) a reaction product of (i) at least one polyamine, (ii) at least one oil soluble polar modified polymer; and (iii) at least one oil soluble high carbon polar modified polymer; (b) water; (c) optionally at least one non-volatile solvent... Agent: L'oreal S.a.

20110286952 - Dermocosmetic composition, aesthetic treatment method using the composition, and use of the composition for lightening the pigmentation of the skin: e

20110286953 - Whitening agent, anti-aging agent, and anti-oxidant agent:

20110286954 - Transfer-resistant emulsion containing a surfactant: The present invention is directed to a transfer resistant and long wear composition containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent capable of solubilizing the oil-soluble polar modified polymer; (e)... Agent: L'oreal S.a.

20110286955 - Emulsion lipstick composition: The present invention is directed to a hydrating and moisturizing solid emulsion lipstick composition, capable of imparting enhanced shine and coverage, containing: (a) at least one polyamine; (b) at least one polar modified polymer; (c) water; (d) at least one non-volatile solvent; (e) at least one wax having a high... Agent: L'oreal S.a.

20110286957 - Multiblock copolymers: Provided herein are multiblock copolymers, as well as micelles and therapeutic compositions thereof.... Agent: University Of Washington

20110286956 - Novel multi-arm polyethylene glycol, preparation method and uses thereof: A novel multi-arm polyethylene glycol (PEG) (I) and preparation method thereof. Active derivatives (II) based on the multi-arm PEG. Gels formed of the active derivatives. Drug conjugates formed of the active derivatives and drug molecules and uses thereof in medical preparation. The multi-arm PEG is formed by polymerizing ethylene oxide... Agent: Beijing Jenkem Technology Co. Ltd.

20110286959 - Copolymers for suppression of autoimmune diseases, and methods of use: Random three- and four-amino acid copolymers having lengths of 14-, 35- and 50-amino acid residues are provided. Fifty-mers of FEAK were effective inhibitors of MBP 85-99- or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones. These copolymers efficiently suppressed the mouse disease EAE, which was induced in a susceptible SJL/J... Agent: President And Fellows Of Harvard College

20110286958 - Hpma polymer platinum chelates: Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer.... Agent: Access Pharmaceuticals, Inc.

20110286960 - Cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf): Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics/pharmacodynamics (PK/PD) models were created and simulated... Agent: Optimata Ltd.

20110286962 - Compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent:

20110286961 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Bristol-myers Squibb Company

20110286963 - Human soluble cd146, preparation and uses thereof: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may... Agent: Universite De La Mediterranee

20110286964 - Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections: The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2,... Agent:

20110286965 - Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections: The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z,... Agent:

20110286966 - Inhibitor of endogenous human interferon-gamma: Modified endogenous human interferon-gamma (hIFN-γ), biologically inactive but preserving binding affinity to the hIFN-γ receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis.... Agent:

20110286967 - Long-acting interferons and derivatives thereof and methods thereof: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.... Agent:

20110286968 - Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided.... Agent:

20110286969 - Deuterated compounds as hepatitis c virus (hcv) inhibitors: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound... Agent: Schering Corporation

20110286970 - Method for treating parkinson's disease: The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease.... Agent: Ramot At Tel Aviv University Ltd.

20110286971 - Targeted drug-carrying bacteriophages: The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of... Agent: Ramot At Tel-aviv University Ltd.

20110286979 - Chemosensitization by bi-functional small hairpin rna (bi-shrna): Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNASTMN1... Agent: Gradalis, Inc.

20110286984 - Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases: Gene encoding human glucokinase mutant is provided. The gene has the nucleotide sequence chosen from the nucleotide sequence listed as SEQ ID NO:2 and the nucleotide sequence wherein the ORF region encodes the same amino acid sequence as the one encoded by ORF region (position 487 to 1884) of SEQ... Agent:

20110286978 - Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof: The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the... Agent:

20110286981 - Glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the... Agent: Zealand Pharma A/s

20110286982 - Glucagon analogues: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the... Agent: Zealand Pharma A/s

20110286983 - Long lasting drug formulations: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.... Agent:

20110286985 - Method of treatment using organotypically cultured skin tissue comprising niks cells that express exogenous hif-1a: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated... Agent: Stratatech Corporation

20110286980 - Methods for inducing selective apoptosis: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by... Agent:

20110286986 - Lactoferrin and angiogenin compositions and uses thereof: Compositions are described which contain lactoferrin and angiogenin. The described compositions are useful in treatment of a variety of conditions, particularly in promoting bone health and relief of menopausal symptoms.... Agent: Naidu Lp

20110286972 - Virus growing in hypoxic cell or virus vector expressing gene therein: The present invention provides a virus or a viral vector capable of expressing a gene specifically in a cell having replication ability in a hypoxic state such as a cancer stem cell and injuring the cell, and pharmaceutical composition comprising the same. Specifically, the present invention provides a virus or... Agent:

20110286976 - Bi-specific fusion proteins: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain... Agent: Merrimack Pharmaceuticals

20110286977 - G6pc2-encoded beta cell surface tags: The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof.... Agent: Novo Nordisk A/s

20110286974 - Method for treating diabetes and other glucose regulation disorders using stem cells: Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells... Agent:

20110286973 - Methods for introducing heterologous cells into fish: The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods are useful for screening potential drugs for toxicity toward introduced... Agent: Phylonix Pharmaceuticals, Inc.

20110286975 - Systems and methods for magnetic guidance and patterning of materials: Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells... Agent:

20110286987 - Quenching methods for red blood cell pathogen inactivation: The present invention provides improved methods for treating red blood cell compositions with a pathogen-inactivating compound under conditions which provide suitable pathogen inactivation while maintaining cell vitality. Also provided methods of reducing dehydration in red blood cells, as well as treated red blood cell compositions.... Agent:

20110286989 - Angiogenin complexes (angex) with lipid-based substrates and uses thereof: Stabilized angiogenin compositions and methods of preparing stabilized angiogenin compositions by immobilization on a lipid-based substrate, such as a phospholipid or Coenzyme-Q10, are disclosed.... Agent: Naidu Lp

20110286988 - Fviii muteins for treatment of von willebrand disease: This invention relates to treatment of von Willebrand Disease by administration of Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic... Agent: Bayer Healthcare LLC

20110286990 - Methods of diagnosing and treating fibrosis: The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition... Agent: University Of Rochester

20110286991 - Peptides derived from hmg-coa reductase and cosmetic and/or pharmaceutical composition containing same: The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to... Agent: Isp Investments Inc.

20110286992 - Personal care composition containing leghemoglobin: A personal care composition comprising leghemoglobin and at least one preservative selected from the group consisting of alcohols, glycols, parabens, hydantoins, quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing agents, and halogenated compounds. Preferably, the leghemoglobin is a nitrogen fixation root nodule extract providing a leghemoglobin concentration in the composition of between 0.0001%... Agent:

20110286993 - Use of hsp70 as a regulator of enzymatic activity: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said... Agent: Orphazyme Aps C/o Cobis A/s

20110286995 - Drug therapy for celiac sprue: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent:

20110286994 - Methods and compositions for improving growth of meat-type poultry: The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinase enzyme extract and animal feed supplements for achieving the same are also provided.... Agent:

20110286996 - Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus... Agent: Vicuron Pharmaceuticals Inc.

20110286997 - Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes: Compositions and methods for the detection and treatment of T1D are provided.... Agent:

20110286999 - Methods for reversing multiple resistance in animal cells: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.... Agent:

20110286998 - Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors: Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and... Agent: Voyager Pharmaceutical Corporation

20110287002 - Antibodies against epidermal growth factor receptor (egfr) and uses thereof: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.... Agent: Adimab, LLC

20110287006 - Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2... Agent: Hoffman-la Roche. Inc.

20110287001 - Method of treatment: The invention provides methods for inducing apoptosis, comprising treatment of a patient with a TNFα inhibitor as well as with an IAP inhibitor and a TRAIL receptor agonist. The methods ameliorate the risk of unwanted effects, thereby resulting in an improved therapeutic index for IAP inhibitors in combination with a... Agent: Amgen Inc.

20110287004 - Mg53 compositions and methods of use: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research... Agent: University Of Medicine And Dentistry Of New Jersey

20110287005 - Monoclonal antibodies against amyloid beta protein and uses thereof: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.... Agent:

20110287007 - Treatment and prevention of chronic asthma using antagonists of integrin alphavbeta6: The present invention relates to methods of asthma treatment and prevention using αvβ6 antagonists, such as αvβ6-binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of αvβ6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection... Agent: The Regents Of The University Of California, A California Corporation

20110287003 - Treatment methods: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.... Agent: Genentech, Inc.

20110287000 - Treatment of autoimmune and inflammatory disease: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding... Agent:

20110287008 - Inhibition of emmprin to treat multiple sclerosis: The present invention provides new methods for the prevention of migration of leukocytes into the CNS. These methods, which rely on inhibition of EMMPRIN activity or expression, can be used to treat or slow the onset of diseases such as multiple sclerosis and EAE.... Agent: Uti Limited Partnership

20110287009 - Production of heteromultimeric proteins: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods... Agent: Genentech, Inc.

20110287017 - Anti-p-selectin antibodies and methods of their use and identification: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which... Agent:

20110287014 - Antibodies directed against calcium channel subunit alpha2/delta and methods using same: The present invention provides compositions comprising antibodies or polypeptides that specifically bind to an epitope in a von Willebrand Factor A (VWF-A) domain of a calcium channel subunit α2δ and induces synaptogenesis and methods of using the compositions for inducing synaptogenesis and neurite outgrowth.... Agent:

20110287011 - Ddr1-binding agents and methods of use thereof: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as... Agent: Oncomed Pharmaceuticals, Inc.

20110287010 - Diagnostic methods and markers: The present invention relates to methods of detecting, monitoring and treating prostate cancer (PRC) OR prostatic intraepithelial neoplasia (PIN) or a predisposition to same. Provided for use in the methods is a novel cancer marker, PSPU43, as well as bioassays and kits.... Agent: Otago Innovation Limited

20110287015 - Mg53 compositions and methods of use: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research... Agent: University Of Medicine And Dentistry Of New Jersey

20110287016 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys, Inc.

20110287012 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc.

20110287013 - Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence... Agent: Intercell Ag

20110287018 - Methods of treating interstitial cystitis: The present invention relates to the use of IL-12 and/or IL-23 inhibitors for the treatment of a pain and/or a lower urinary tract symptom(s) (LUTS) associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome.... Agent:

20110287019 - Therapeutic targeting of escort proteins: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface,... Agent: Functional Genetics, Inc.

20110287021 - Neoplasm specific antibodies and uses thereof: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.... Agent: Patrys Limited

20110287020 - Recombinant vectors: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.... Agent: Tocagen Inc.

20110287025 - Combination therapy and method for assessing resistance to treatment: The present invention relates to a method for determining a subject's resistance to treatment with 2,2-dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide by measuring the levels a biomarker or biomarkers present in a biological sample obtained from the subject, the biomarker being IL6 and/or IL8. The present invention also relates to a combination therapy for a... Agent:

20110287023 - High affinity antibodies against hmgb1 and methods of use thereof: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present... Agent: Medimmune, LLC

20110287022 - Interferon alpha-induced pharmacodynamic markers: The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder,... Agent: Medlmmune, LLC

20110287028 - Methods of treatment using human anti-il-23 antibodies: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.... Agent:

20110287027 - Pain treatment: The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF... Agent: The University Of Melbourne

20110287026 - Sirt4 and uses thereof: Provided herein are SIRT4 compositions and methods of use thereof. The invention provides functional information for use in the identification and design of compounds that modulate SIRT4 enzyme activity (e.g., inhibition of fatty acid oxidation, ADP ribosylation, and/or downregulation of glutamate dehydrogenase), and to the compounds identified by such methods... Agent: President And Fellows Of Harvard College

20110287024 - Vascular endothelial cell growth factor antagonists: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.... Agent: Genentech, Inc.

20110287030 - Compositions and methods for diagnosing and treating an inflammation: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in... Agent: Rappaport Family Institute For Research In The Medical Sciences

20110287029 - Inhibition of the beta3 subunit of l-type ca2+ channels: The present invention provides reagents and methods for identifying inhibitors of the L-type Ca2+ channel β3 protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin... Agent: Biocrine Ab

20110287031 - Covalently reactive transition state analogs and methods of use thereof: Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed.... Agent:

20110287035 - Method and composition for hyperthermally treating cells: A method and composition for hyperthermally diagnosing and monitoring treatment of cells in an animal with photoacoustic sound and nanoparticles. The heat (temperature) and photoacoustic sound wave production inside the target tissue is measured. The desired temperature is achieved using a laser and photoacoustic imaging technique. Hyperthermia treatment of tissue... Agent:

20110287032 - Novel ctla4-ig immunoadhesins: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.... Agent: Xencor, Inc.

20110287034 - Therapeutic and diagnostic methods relating to cancer stem cells: Genes that are deregulated in cancer stem cells (e.g., melanoma stem cells) are disclosed. Methods which involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes are used to treat individuals having melanoma. Cell surface genes that are upregulated in melanoma stem cells are targeted... Agent: The Brigham And Womens Hospital, Inc.

20110287033 - Use of ferritin to treat iron disorders: Methods and compositions for treating an iron disorder in a patient are presented, including methods for delivering a therapeutically effective amount of iron to the brain. Iron disorders that may be treated by these methods include iron deficiency disorders and iron overload disorders. A recombinant yeast expressing human H-ferritin and... Agent:

20110287036 - Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound: The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.... Agent: National Cancer Center

20110287039 - Expression system for modulating an immune response: The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least... Agent: The University Of Queensland

20110287038 - Method for treating solid tumors: Provided herein are methods for treating a solid tumor in a subject in need thereof by activating an immune response against a tumor antigen. Also provided are methods for treating a solid tumor in a subject in need thereof by activating antigen-presenting cells and eliciting an immune response against a... Agent:

20110287037 - Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof: The invention relates to a microorganism as a carrier of nucleotide sequences coding for antigens and protein toxins comprising the following components: (I) at least one nucleotide sequence coding for at least one complete or partial antigen of at least one wild-type or mutated protein; and (II) at least one... Agent: Zentaris Gmbh

20110287042 - A-beta immunogenic peptide carrier conjugates and methods of producing same: The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and... Agent: Janssen Alzheimer Immunotherapy

20110287041 - Aldehyde tags, uses thereof in site-specific protein modification: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as... Agent:

20110287040 - Materials and methods for treatment of inflammation: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P... Agent:

20110287043 - Melanoma antigens and their use in diagnostic and therapeutic methods: The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to... Agent: The U.s.a., As Represented By The Secretary, Dept. Of Health And Human Services

20110287044 - Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv: The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV,... Agent:

20110287045 - Enhanced immune response against infections: The present invention relates to the discovery that Tat polypeptides may be used as immunoregulators to enhance the immune response to infectious diseases. More particularly, Tat polypeptides may be used as immunoregulators to enhance immune responses to microbial infections, for example, viral and bacterial infections. In accordance with the present... Agent:

20110287046 - Modified streptococcus pneumonia pneumolysin (ply) polypeptides: This disclosure relates to modified Streptococcus pneumonia pneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by S. pneumonia. The modified pneumolysm proteins comprise ammo acid substitutions at threonine 65, glycine 293 and cysteine 428... Agent:

20110287047 - Cross-beta structures as carrier in vaccines: The invention provides means and methods for producing and/or selecting immunogenic compositions, comprising providing said composition with at least one epitope for a B-cell receptor and/or at least one epitope for a T-cell receptor, coupled to a protein that comprises at least one crossbeta structure, and testing at least one... Agent: Crossbeta Biosciences B.v.

20110287048 - Antigen specific tregs and related compositions, methods and systems: Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and... Agent:

20110287049 - Prevention and treatment of amyloidogenic diseases: Active immunotherapy methods for treating a human patient having an amyloid disease characterized by the presence of amyloid fibrils comprising islet amyloid polypeptide (IAPP).... Agent: Elan Pharmaceuticals, Inc.

20110287051 - Parapoxvirus vectors: The present invention relates to recombinant parapoxviruses which carry in their genomes comprising heterologous DNA derived from a rabies virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates to the use of recombinant parapoxviruses for diagnostics.... Agent: Pfizer Inc.

20110287050 - Recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi: The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant... Agent: Universite De Liege, Faculty Of Veterinary Medicine Immunology-vaccinology

20110287052 - Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae: The invention encompasses a recombinant bacterium capable of eliciting an immune response against Streptococcus pneumoniae, a vaccine comprising the bacterium, and methods of using the bacterium.... Agent: The Arizona Board Of Regents For And On Behalf Of Arizona State University

20110287053 - Recombinant foot and mouth disease vaccine: A foot and mouth disease virus (FMDV) vaccine and method for producing same is described wherein the N terminal portion of the FMDV polyprotein, encoding the four structural proteins, 1A, 1B, 1C, and 1D, are each separated by a non-FMDV protease, preferably a cellular protease, for example, furin. The expression... Agent:

20110287054 - Multivalent adjuvanted influenza virus compositions: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen... Agent: Glaxosmithkline Biologicals, S.a.

20110287055 - Compositions comprising prfa* mutant listeria and mehtods of use thereof: The invention provides recombinant Listeria that constitutively express Prf A and comprise polynucleotides that encode polypeptides such as tumor or infectious agent antigens, operably linked to a PrfA responsive regulatory agent. Methods of using the Listeria, and compositions thereof, to induce or enhance an immune response and/or in the treatment... Agent: Aduro Biotech

20110287056 - Agents and methods to elicit anti-tumor immune response: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or... Agent: The Trustees Of Columbia University In The City Of New York

20110287057 - Cancer treatment: A cell-based vaccine prolongs the survival of cancer patients. The vaccine includes a dose of irradiated cultured lung adenocarcinoma cells (AD100) transfected with HLA A1 and gp96-Ig (human gp96 wherein the endoplasmic reticulum retention signal, KDEL, is replaced with the Fc-portion of human IgG1 and was injected intradermally into patients... Agent: University Of Miami

20110287058 - Universal gm-csf expressing bystander human cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition.... Agent: The Johns Hopkins University School Of Medicine

20110287059 - Honey analysis: A number of methods of analysing honey are described to determine the age of the honey, the presence of fortification with additives including methylglyoxal (MGO), the region from which the honey is derived, the plant species from which the honey is derived and whether the honey has been heated during... Agent: Comvita New Zealand Limited

20110287064 - Antibiotic coating: An implant is provided having an antibiotic coating that is inexpensive and easy to manufacture. The antibiotic coating adheres well and in stable manner to the surface of the implant, can be degraded by the body without forming toxic products, prevents the crystallization of the antibiotics in the coating, and... Agent: Heraeus Medical Gmbh

20110287070 - Bone repair material and method for producing the same: Bone repair materials are disclosed, from which ions are hardly eluted in living body and which are superior in apatite-forming ability and resistance to apatite peeling and have a scratch resistance high enough for practical use. The material comprises a substrate made of titanium or titanium alloys, and a surface... Agent: Sagawa Printing Co., Ltd.

20110287062 - Chewable formulation comprising alginate, bicarbonate and carbonate: The present invention relates to a solid, ingestible composition comprising a) an alginate; b) a bicarbonate; and c) a carbonate wherein the composition is in the form of a chewable core, a process for preparing said composition, and its use in the treatment of reflux oesophagitis, gastritis, dyspepsia or peptic... Agent: Reckitt Benckieser Healthcare (uk) Limited

20110287061 - Dietary composition and method for promoting healthy hair growth and melanogenesis: A dietary composition for promoting melanogenesis in hair of a user comprising approximately 5,000 IU per day of catalase, a synergistic core component, 5-α-reductase inhibitors, an antioxidant component, and approximately 200 mg per day of L-tyrosine. Preferably, the synergistic core component comprises copper, vitamin B6, biotin, para-aminobenzoic acid, folic acid,... Agent:

20110287060 - Erythritol-based hard coatings: The present invention relates to a coated product comprising a core and a hard coating surrounding the core, wherein the hard coating is composed of at least one coating layer, which comprises erythritol and one or more crystallization modifiers, a process for preparing such a coated product, and the use... Agent: Cargill Inc

20110287068 - Fibrin and fibrinogen matrices and uses of same: There is provided compositions-of-matter comprising fibrin or fibrinogen crosslinked with at least one reducing sugar.... Agent: Ramot At Tel-aviv University Ltd.

20110287063 - Methods for prevention and treatment of inflammation using anti-chemokine antibodies: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.... Agent: Morehouse School Of Medicine

20110287071 - Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20110287065 - Nanoparticulate cinacalcet compositions: The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.... Agent: Elan Pharma International Limited

20110287066 - Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers: Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which... Agent: Basf Se

20110287072 - Prebiotic formulations and methods of use: The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition... Agent: Ritter Pharmaceuticals, Inc.

20110287067 - Reinforced adhesive complex coacervates and methods of making and using thereof: Described herein is the synthesis of reinforced adhesive complex coacervates and their use thereof. The reinforced adhesive complex coacervates are composed of (a) at least one polycation, (b) at least one polyanion, and (c) a reinforcing component. The adhesive complex coacervates described herein can be subsequently cured to produce strong,... Agent: University Of Utah Research Foundation

20110287069 - Solid oral formulations of a pyridopyrimidinone: A solid oral dosage pharmaceutical formulation of (R)-2-Amino-7-[4-fluoro-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one or its salt; and a surfactant or an acid.... Agent:

20110287074 - Antimicrobial compositions, methods of manufacture thereof and articles comprising the same: Disclosed herein are a variety of applications for an antimicrobial agent. The antimicrobial agent comprises a silanol containing molecule, the silanol containing molecule comprising silanols (R1R2R3SiOH), siloxanediols HO(R1R2SiO)nH, siloxanols HO(R1R2SiO)nSiR1R2R3 or combinations thereof, where R1, R2 and R3 are selected from alkyl or fluoroalkyl moieties having 1 to 4 carbon... Agent: University Of Florida Research Foundation, Inc.

20110287076 - Deformed shaped particles and method for producing the same: s

20110287075 - Electricity-generating particulates and the use thereof: The invention features a galvanic particulate including a first conductive material and a second conductive material, wherein both the first conductive material and the second conductive material are exposed on the surface of the particulate, wherein the particle size of the particulate is from about 10 nanometers to about 100... Agent:

20110287073 - Emulsion concentrate: The present invention relates to an emulsion concentrate with content of water-insoluble oil components (A), of hydrophilic non-ionic emulsifiers (B), of lipophilic co-emulsifiers (C), of polyols (D) and water, which comprises less than 50% by weight of water-insoluble oil component (A)—based on the total weight of the concentrate—comprising components (A),... Agent: CognisIPManagement Gmbh

20110287077 - Embedded biocide: A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris(hydroxyorgano)phosphine (THP), a THP+ salt (tetrakis(hydroxyorgano)phosphonium salt) or a condensate of THP and a nitrogen containing compound. The compound may be used to reduce the number of microorganisms in industrial systems... Agent: Rhodia Uk Limited

20110287078 - Novel porous biomaterials: The invention provides porous biomaterials and methods for forming porous biomaterials. The porous biomaterials of the invention comprise a biocompatible polymer scaffold defining an array of pores, wherein substantially all the pores have a similar diameter, wherein the mean diameter of the pores is between about 20 and about 90... Agent: University Of Washington

20110287079 - Supporting material for cell sheet: Provided in one embodiment is an implantable support material for culturing cells, wherein at least some of the cells substantially maintain at least one of (i) phenotype and (ii) genotype thereof after being cultured on the support material.... Agent: Xylos Corporation

20110287080 - Coating ii: The invention relates to a coating composition for an implantable medical device, a method of coating a medical device and a device coated with the composition.... Agent: Smith & Nephew PLC

20110287081 - Bolus: The present invention relates to a bolus for administration to a ruminant by deposition into its rumen, wherein the bolus has a construction including: a) a casing; b) a core inside the casing wherein the core is formed from at least two tablets; and, is characterised in that a permanently... Agent: Bomac Research Limited

20110287083 - Bioabsorbable composition and coatings including same: Bioabsorbable compositions of A) blends of bioabsorbable homopolymers and/or copolymers containing glycolide and lactide and B) salts of fatty acids and/or fatty acid esters are described. Processes for making the compositions and surgical articles made totally or in part therefrom, including suture coatings, are also described.... Agent: Tyco Healthcare Group Lp

20110287082 - Multilayer scaffold: The invention generally relates to biodegradable and/or bioresorbable fibrous articles and more particularly to products and methods having utility in medical applications.... Agent:

20110287090 - Compositions and methods for inhibiting expression of a mutant gene: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a mutant gene, comprising a first strand that has a complementary region that is complementary to at least a portion of an RNA transcript of at least part of the mutant target gene and a... Agent:

20110287085 - Liposomal curcumin for treatment of cancer: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery... Agent: Board Of Regents, The University Of Texas System

20110287084 - Method for reducing body fat and increasing lean body mass by reducing stearoyl-coa desaturase 1 activity: It is disclosed here that inhibiting the activity of the enzyme stearoyl-CoA desaturase (SCD1) in an animal causes the animal to have less body fat and greater lean body mass. The lower of SCD1 activity level can be accomplished by inhibiting activity of the enzyme or lowering levels of active... Agent:

20110287087 - Modified cationic liposome adjuvans: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used... Agent: Statens Serum Institut

20110287088 - Modulation of olfml-3 mediated angiogenesis: The present invention relates to nucleic acids and antibodies against Olfml-3 and Olfml-3 protein function in angiogenesis. Angiogenesis-related conditions, such as cancer or wound healing, can be treated by the composition comprising the Olfml-3 antagonists or agonists, respectively.... Agent: Research Development Foundation

20110287086 - Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo: The present invention includes compositions and methods for regenerating glucose-responsive cells by ultrasound-targeted microbubble destruction in the pancreas, wherein the composition comprises a pre-assembled liposome-nucleic acid complex in contact with in and about a microbubble, wherein the pre-assembled liposome-nucleic acid complex comprises a NeuroD gene under the control of the... Agent:

20110287089 - Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation: The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient the immune response toward a Th1 type response directed against said antigen, more particularly for the prevention and/or the treatment of cancer,... Agent:

20110287091 - Chronotherapeutic pharmaceutical composition: The present invention relates to chronotherapeutic pharmaceutical compositions and a method of preparing the same. The composition comprises of at least one active ingredient, a pH independent agent and a hydrophilic agent. The active ingredient in the composition is coated with the pH independent agent. The composition provides a dual... Agent: Abbot Healthcare Private Limited

20110287092 - Compositions comprising decitabine and tetrahydrouridine and uses thereof: Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described.... Agent: The Board Of Trustees Of The University Of Illinois

20110287093 - Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats: The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.... Agent:

20110287094 - Specific time-delayed burst profile delivery system: The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent; a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein; and a first inner coating... Agent: Dexcel Pharma Technologies Limited

20110287095 - Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.... Agent: Mallinkckrodt Inc.

20110287096 - Modified gastroretentive drug delivery system for amine drugs: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of... Agent: Abon Pharmaceuticals, LLC

20110287097 - Pharmaceutical compositions comprising ropinirole: Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form.... Agent: Dr. Reddy's Laboratories Limited

20110287098 - Dissolution stability of calcium carbonate tablets: ii) compressing said composition using a tabletting machine equipped with at least one pair of punches and dies, wherein the pair of punches and die before filling the die with said particulate composition is sprayed with a composition comprising a lubricant selected from magnesium stearate, calcium stearate or stearic acid... Agent: Nycomed Pharma As

20110287100 - Galenic formulations of organic compounds: A solid unit dosage form of aliskiren for oral administration in the form of a tablet having a core and an outer coating is prepared such that the core contains a therapeutically effective amount of aliskiren and the outer coating is in the form of a film-coat with taste masking... Agent:

20110287101 - Rapid release mini-tablets provide analgesia in laboratory animals: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in... Agent: The Johns Hopkins University

20110287099 - Sustained-release formulations of topiramate: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects... Agent: Supernus Pharmaceuticals, Inc.

20110287102 - Chain extenders: a

20110287103 - Sustained-release formulations of topiramate: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects... Agent: Supernus Pharmaceuticals, Inc.

20110287104 - Process for the production of an n-butyric acid compound in micro encapsulated form, for animal or human consumption: A process for the production of an n-butyric acid compound in microencapsulated form comprises the stages of:—providing a granular material based on the n-butyric acid compound, —mixing the granular material with a matrix having a content of long-chain C14-C22 saturated fatty acids of from 40% to 95%, and an amount... Agent:

20110287105 - Composition comprising biodegradable polymers for use in a cosmetic composition: The present invention relates to certain novel polymer powder compositions suitable for personal care and cosmetic compositions. The present invention also relates to cosmetic compositions comprising such novel polymer powders. The present invention also relates to processes for manufacturing the polymer powders, methods of making cosmetic and personal care compositions... Agent: Micro Powders, Inc.

20110287106 - Cognitive impairment ameliorant: A cognitive impairment ameliorant is provided that is useful for the prevention or treatment of cognitive impairment, and particularly Alzheimer's disease. The cognitive impairment ameliorant contains royal jelly as an active ingredient thereof.... Agent:

20110287107 - Porous bioceramic composition for bone repair: The present invention relates to a porous bioceramic composition for bone repair and method of fabrication of the same. 3D-scaffolds were fabricated with a novel micro- and macro-architecture. Porous scaffolds based on dextrin, dextran, gelatin and biomineral (CaCO3) powder were fabricated by heating and freeze-drying methods. Fabrication of different compositions... Agent: Universiti Putra Malaysia

20110287108 - Pesticide composition comprising a tetrazolyloxime derivative and a fungicide or an insecticide active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative... Agent: Bayer Cropscience Ag

20110287109 - Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products: The present invention provides compositions comprising vitamins, minerals, nutrients, sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.... Agent: Max International, LLC

20110287110 - Combination cancer treatment: Described herein are methods of inhibiting the proliferation of cancer cells and methods of treating cancer, by administering a combination of a copper chelator and a platinum-based chemotherapeutic.... Agent:

20110287112 - Prostate cancer progression inhibitor and progression inhibition method: A prostate cancer progression inhibitor comprises 4-(4-cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid, a salt thereof, a solvate thereof, or a prodrug thereof. 4-(4-Cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid is useful as a prostate cancer progression inhibitor because this butyric acid has, for example, a growth inhibiting effect and a hormone responsiveness recovering effect on prostate cancer that has... Agent: Kyoto University

20110287111 - Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds: The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino)purines.... Agent:

20110287113 - Treatment of psoriasis: The invention relates to an aqueous composition capable of delivering nitric oxide for use in the treatment of psoriasis, particularly plaque psoriasis, e.g. by application of a skin dressing.... Agent: Insense Limited

20110287114 - Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition: A method of making a gelled composition that includes combining water and an effervescent tablet in a vessel, the effervescent tablet including at least 200 mg gelatin and an effervescent couple that includes an acid and a base, heating an aqueous composition (e.g., in a microwave oven), optionally adding cold... Agent: Amerilab Technologies, Inc.

20110287115 - Standardization of botanical products utilizing biological activity as a marker: The present invention relates generally to herbal materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. Particularly, the present invention relates generally to Hydrstatis canadensis (goldenseal) materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention... Agent:

20110287116 - Use of jasmonates for treating heart failure and related cardiac disorders: A formulation comprising jasmonate for improving cardiac muscle function, particularly by modulating myocardial contractility in a subject is disclosed. Such a formulation may be used to treat a heart or cardiac related disorder.... Agent: Broady Health Sciences LLC

20110287117 - Adjuvant therapy in the treatment of gouty arthritis: This invention relates to the treatment of gouty arthritis with cherry juice concentrate.... Agent: University Of Medicine And Dentistry Of New Jersey

20110280798 - Cell penetrating peptides for intracellular delivery: The present invention provides a cell penetrating peptide which has following sequence: NYBX1BX2BNQX3, wherein B represents a basic amino acid, X1 represents an amino acid with an aromatic, a hydrophobic or an uncharged side chain, X2 represents any amino acid, and X3 represents N or none. The present invention also... Agent: National Tsing Hua University

20110280799 - Nanocells for diagnosis and treatment of diseases and disorders: The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells... Agent: Massachusetts Institute Of Technology

20110280800 - Il-1 binding proteins: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.... Agent: Abbott Laboratories

20110280801 - Methods and compositions for f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled by the described methods. Preferably, the F-18 may be conjugated to... Agent: Immunomedics, Inc.

20110280802 - Linkers for radiopharmaceutical compounds: A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N—O—P-Q,... Agent: Bracco Imaging S.p.a.

20110280803 - Radioiodination method: The present invention provides a method for the synthesis of radioiodinated compounds which is advantageous over prior art methods. Using a hydrazine or an aminoxy in place of a primary amine for indirect radioiodination facilitates a much quicker reaction thus reducing reaction time and increasing the yield. In addition, where... Agent: Ge Healthcare Uk Limited

20110280804 - Highly selective sigma receptor radioligands: wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate,... Agent: University Of Mississippi

20110280806 - Dye conjugate imaging agents: The present invention relates to imaging agents suitable for in vivo optical imaging, which comprise conjugates of dihydrocarbazolium dyes with biological targeting moieties, such as peptides. Also disclosed are pharmaceutical compositions and kits, as well as in vivo imaging methods. The dihydrocarbazolium dyes are functionalised with water solubilising groups and... Agent:

20110280805 - Neurotoxic sterol glycosides: The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof, in animal models of neurodegenerative disease. Neurotoxicity-modulating chromenols can also be used in these animal models... Agent: Neurodyn, Inc.

20110280807 - Methods and models for stress-induced analgesia: The invention disclosed relates to methods and models for enhancing stress-induced analgesia through non-opioid mechanisms.... Agent: University Of Georgia Research Foundation, Inc.

20110280808 - Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins: The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the... Agent: Ac Immune, S.a.

20110280809 - Pdia4, target of cytopiloyne derivatives, for tumor diagnosis and treatment: Methods of diagnosing cancer that are based in part on the findings that Pdia4 promotes cell growth, cell proliferation, and cell cycle are disclosed herein. Methods of using microvessel density as a surrogate marker and reducing tumor microvessel density in a subject are also enclosed herein.... Agent: Academia Sinica

20110280811 - Method of measuring propulsion in lymphatic structures: Novel methods and imaging agents for functional imaging of lymph structures are disclosed herein. Embodiments of the methods utilize highly sensitive optical imaging and fluorescent spectroscopy techniques to track or monitor packets of organic dye flowing in one or more lymphatic structures. The packets of organic dye may be tracked... Agent:

20110280810 - Surgical optical systems for detecting brain tumors: A method of detecting a brain tumor includes administering indocyanine green to a living body; exposing brain tissue in the living body; irradiating the exposed brain tissue with excitation light of indocyanine green; obtaining an image based on fluorescence of the excited indocyanine green in the brain tissue, wherein the... Agent: Carl Zeiss Surgical Gmbh

20110280812 - Flavor-enhancing amide compounds: wherein R and R′ is independently selected from the group consisting of H and C1-C10 linear, branched, or cyclic alkyl, alkenyl, alkynyl or aromactic groups. Thus, the amide compounds of the present invention can be used to enhance or modify the flavor of orally consumable compositions, such as foodstuff, chewing... Agent:

20110280813 - Neuraminidase inhibitors and uses thereof: The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors.... Agent:

20110280814 - Process for making improved oral compositions: Processes for preparing an oral care composition having improved taste, color, odor and/or clarity, wherein said processes comprise the steps of: providing an unfiltered dentifrice component selected from unfiltered alkyl phosphate surfactants, alkyl phosphate ethoxylated surfactants, lauryl sulfate surfactants, betaine surfactants, antibacterial agents, cetyl pyridinium chloride, metal Salts, phytic acids,... Agent:

20110280815 - Composition for inhibiting melanin production and application thereof: o

20110280817 - Compositions containing hyperbranched polyol and acrylic film former: The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol and at least one acrylic film forming agent, as well as to methods of using such compositions.... Agent: L'or&#xe9 Al S.a.

20110280818 - Compositions containing hyperbranched polyol and tackifier: The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol and at least one tackifier, as well as to methods of using such compositions.... Agent: L'oreal S.a.

20110280816 - Compositions containing hyperbranched polyol, acrylic film former and alkoxylated mixed polyester: The invention relates to a composition, especially a cosmetic composition, comprising at least one hyperbranched polyol, at least one acrylic film forming agent, and at least one alkoxylated mixed polyester, as well as to methods of using such compositions.... Agent: L'oreal S.a.

20110280821 - Hair care solution forming a film protecting natural hair from gluing products: The hair gluing product of the invention is gel or crystallizing protective growth serum that dries down to form a film over your natural hair and scalp. The invention allows for application of hair bonding glue without damaging natural hair or scalp. It contains aloe extract, tea tree oil, chamomile... Agent:

20110280820 - Long-wear, waterproof mascara composition: The present invention is directed to a long wear, waterproof eye makeup composition having a creamy texture and feel containing: (a) at least one polyamine; (b) an oil-soluble polar modified polymer; (c) water; (d) at least one non-volatile oil capable of solubilizing the oil-soluble polar modified polymer; (d) at least... Agent: L'oreal S.a.

20110280823 - Composition: Concentrated shampoo composition comprising from 32 to 38% wt. cleansing surfactant and from 0.5 to 3% wt. coconut oil or palm kernel oil and wherein the composition has a zero shear viscosity of from 2 to 2000 Pa·s and comprises 90% vol. or more composition in the nematic discotic phase.... Agent:

20110280822 - Structured surfactant system: An aqueous structured surfactant composition contains an anionic surfactant selected from isethionate surfactants, taurate surfactants, and sarcosinate surfactants, and mixtures thereof, and an electrolyte and is useful in personal care applications.... Agent:

20110280819 - Washable eye makeup composition having waterproof and smudge-resistant properties: The present invention is directed to a washable eye makeup composition having waterproof and smudge-resistant properties containing: (a) at least one oil-soluble polar modified polymer; (b) at least one polyamine; (c) at least one alkyl ethoxylated polymer wax; (d) water; (e) at least one non-volatile solvent capable of solubilising the... Agent: L'oreal S. A.

20110280824 - Furanone copolymers: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.... Agent: Tyco Healthcare Group Lp

20110280825 - Extracorporeal devices and methods of treating complications of pregnancy: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.... Agent: Beth Israel Deaconess Medical Center

20110280827 - Methods and compositions for treating hematological malignancies: The invention relates to methods and compositions for treating a subject afflicted with a hematological malignancy using a combination of a CXCR4 antagonist and an immunotherapeutic agent.... Agent:

20110280826 - Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.... Agent: Biosteed Gene Expression Tech Co. Ltd

20110280828 - Methods for treatment of microbial disorders: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.... Agent:

20110280829 - Low molecular weight sulphated polysaccharides as candidates for anti-angiogenic therapy: Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to... Agent: Therapol

20110280830 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Human Genome Sciences, Inc.

20110280831 - Combinations comprising methotrexate and dhodh inhibitors: dently selected from hydrogen atom, linear or branched C1-4 alkyl groups, C3-7 cycloalkyl groups, or R7 and R8 together with the nitrogen atom to which they are attached form a group of formula wherein n is an integer from 0 to 3 or, when G′ represents CR6, G2 together with... Agent:

20110280832 - Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders: The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin... Agent: The Medical Research, Infrastructure, And Health S Ernices Fund Of The Tel Aviv Medical Center

20110280833 - Peptides, derivatives and analogs thereof, and methods of using same: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment... Agent: Curedm Group Holdings, LLC

20110280834 - Methods and compositions for cardiac tissue regeneration: Methods for treating an injured cardiac tissue in a subject are provided herein. Methods for improving survival, engraftment and proliferation of stem cells in a cardiac tissue are provided. Also provided are methods for generating cardiac cells. Further provided are compositions for generating cardiac cells in a subject.... Agent: Cedars-sinai Medical Center

20110280835 - Commensal bacteria as signal mediators within a mammalian host: Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganism to prevent or ameliorate diseases are also provided. The genetically engineered cells or microorganisms can be engineered to express a signal and used to interrupt... Agent:

20110280836 - Compositions for bacterial mediated gene silencing and methods of using the same: The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The... Agent:

20110280844 - Hepatocyte production by forward programming: The invention generally features methods for providing hepatocytes from a variety of cell sources, particularly pluripotent stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects.... Agent: Cellular Dynamics International, Inc.

20110280846 - Olfactory epithelial-derived stem cells and methods of use therefor: The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing... Agent:

20110280845 - Treatment of rheumatoid arthritis using placental stem cells: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.... Agent:

20110280837 - Bifidobacterium longum and hippocampal bdnf expression: The present invention relates in general to edible compositions comprising probiotics. One embodiment of the present invention relates to an edible composition comprising Bifidobacterium longum ATCC BAA-999. This composition can be used to attenuate reductions in hippocampal BDNF expression and/or to treat or prevent anxiety and related disorders.... Agent: Nestec S.a.

20110280839 - Entomopathogenic fungi and uses thereof: The present invention provides a strain of entomopathogenic Beauveria bassiana, compositions comprising the entomopathogenic fungi strain or metabolites of the strain, and the use of the entomopathogenic fungi strain and compositions as biological control agents. Methods for the biological control of phytopathogenic insects using an entomopathogenic Beauveria bassiana fungi strain... Agent: Pwc Tower

20110280838 - Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells: Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells and optionally a hydrogel. In some embodiments, administering the cells promotes... Agent: Advanced Technologies And Regenerative Medicine, LLC

20110280840 - Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota: The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.)... Agent: New York University

20110280847 - Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth: Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of C. difficile spores and/or the growth of C. difficile cells. The methods and compositions of the invention are useful for preventing and treating C. difficile-associated diseases, including but not limited to C.... Agent: Tufts University

20110280848 - Composition comprising chicoric acid and/or derivatives thereof: The present invention relates generally to the field of food and drinks. In particular, for example, a composition is provided that allows to provide tartaric and/or caffeic acid to a subject. One embodiment of the present invention is a composition comprising an ingredient containing chicoric acid and/or derivatives thereof, and... Agent: Nestec S.a.

20110280841 - Electroprocessing in drug delivery and cell encapsulation: The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances... Agent: Virginia Commonwealth University Intellectual Property Foundation

20110280842 - Methods of reprogramming cells: The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to... Agent: Presidents And Fellows Of Harvard College

20110280843 - Treatment of diseases and disorders using placental stem cells: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.... Agent: Anthrogenesis Corporation

20110280849 - Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.... Agent: Anthrogenesis Corporation

20110280851 - Compositions comprising cranberry extract and methods of use thereof: Described herein are compositions that comprise cranberry extract and are potent and low in calories. Methods of preventing or treating infections by administering the described compositions are also provided.... Agent:

20110280850 - Compositions containing dna repair enzyme and anogeissus extract: A topical composition comprising at least one extract from the Anogeissus genus and at least one DNA repair enzyme and a method for treating human skin for improvement comprising applying to the skin a topical composition comprising at least one extract from the Anogeissus genus and at least one DNA... Agent:

20110280852 - Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline: A composition for treating, ameleliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death... Agent: Nitromega Corp.

20110280854 - Compositions and methods for the treatment or the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces: Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include... Agent:

20110280853 - Compositions and methods for treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces: Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include... Agent:

20110280855 - Vitamin c compositions: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives,... Agent:

20110280856 - Treatment of alpha-galactosidase a deficiency: The invention provides highly purified α-Gal A, and various methods for purifying it; α-Gal A preparations with altered charge and methods for making those preparations; α-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an... Agent:

20110280857 - Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister... Agent:

20110280859 - Preventing and treating sepsis: Provided are polypeptides comprising a variant activated protein C comprising one or more amino acid substitutions selected from the group consisting of K146R, D172N, C212R, K146G, R147G, R177G and combinations thereof. Also provided are nucleic acids encoding the polypeptides, and cells, compositions and kits containing the polypeptides and nucleic acids.... Agent: University Of Rochester

20110280858 - Treatment of wounds: The invention generally provides compositions, kits, pharmaceuticals, and methods that promote and enhance wound healing. Such compositions comprise isolated trypsinogen or trypsin polypeptides or isolated polypeptides obtainable from the excretions/secretions (ES) of Lucilia sericata.... Agent: The Secretary Of State For Defence

20110280866 - Anti-cd 160 monoclonal antibodies and uses thereof: The present invention concerns an antibody or fragment thereof, capable of binding to CD 160, said antibody comprising a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: (i) the light chain CDR1: QSISNH (SEQ ID NO: 1), (ii) the light chain CDR2:... Agent: Monoclonal Antibodies Therapectics

20110280865 - Ets-2 biomarkers for fibrotic diseases and uses thereof: Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.... Agent: The Ohio State University

20110280862 - Gep and drug transporter regulation, cancer therapy and prognosis: Described herein are methods for manipulating GEP and/or drug transporters (e.g., ABCB5 and/or ABCF1) on a cell, as well as related products. Also described herein are methods for treating cancer cells using GEP and/or drug transporter and/or their binding molecules and suppression thereof. Methods of cancer treatment targeting the GEP... Agent: The University Of Hong Kong

20110280867 - Heterocyclic aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering Corporation

20110280864 - Low viscosity highly concentrated suspensions: The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension... Agent: Board Of Regents, The University Of Texas System

20110280861 - Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion: Embodiments of the invention relate to methods and compositions for the expansion of hematopoietic stem cell (HSC) self renewal. The microRNA-125a is a master control of HSC self-renewal. Increased expression of mir-125a increased HSC self-renewal by 6-30 folds. Increased expression of mir-125a can be used to expand HSC ex vivo... Agent: The General Hospital Corporation

20110280863 - Methods and compositions for the detection and treatment of preeclampsia: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.... Agent: Yale University

20110280860 - Pharmaceutical compositions comprising monoterpenes: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene)... Agent: Neonc Technologies Inc.

20110280875 - Antibodies which bind human cxcr3: Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also... Agent: Millennium Pharmaceuticals, Inc.

20110280870 - Hepatocyte growth factor receptor antagonists and uses thereof: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,... Agent: Genentech, Inc.

20110280873 - Mcp1-ig fusion variants: The present invention provides, in part, MCP1-Ig fusion polypeptides exhibiting surprisingly beneficial properties as well as methods for treating various diseases (e.g., inflammatory diseases) by administering any of such fusions.... Agent: Schering Corporation

20110280871 - Methods for prevention and treatment of inflammation using anti-chemokine antibodies: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.... Agent: Morehouse School Of Medicine

20110280872 - Methods for prevention and treatment of inflammation using anti-chemokine antibodies: It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.... Agent: Morehouse School Of Medicine

20110280869 - Methods of preventing or treating inflammatory or autoimmune disorders by administering cd2 antagonists in combination with other prophylactic or therapeutic agents: The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof comprising administering... Agent: Medimmune, LLC

20110280868 - Methods of preventing or treating t cell malignancies by administering anti-cd2 antagonists: The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the... Agent: Medimmune, LLC

20110280874 - Modulating angiogenesis: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse.... Agent:

20110280876 - Mutated netrin - 4, fragments thereof and their use as medicines: A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can... Agent: Centre National De La Recherche Scientifique

20110280877 - Inhibition of b7-h1/cd80 interaction and uses thereof: The present invention provides a composition comprising an agent which specifically blocks interaction between B7-H1 and CD80 but not interaction between B7-H1 and PD-1 and a vaccine, optionally in a pharmaceutically acceptable carrier. Further provided is a method of treating or inhibiting abnormal cell proliferation or a viral infection in... Agent:

20110280878 - Substance specific to human pd-1: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein... Agent: Ono Pharmaceutical Co., Ltd.

20110280879 - Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies: The invention provides a chimeric peptide or mixture of chimeric peptides that can be formulated as an immunizing composition and used in a method for immunization of a mammal against an internal peptide cleavage product derived from a precursor or mature protein, for which the peptide cleavage product and the... Agent: Intellect Neurosciences, Inc.

20110280882 - Leukolectins and uses thereof: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.... Agent: Leukolect As

20110280881 - Novel anti-hsp90 monoclonal antibody: [Summary] The present invention relates an anti-HSP90 antibody and use thereof, more specifically to an anti-HSP90 antibody capable of recognizing cell surface HSP90, a vaccine that utilizes the antibody, a drug that utilizes the antibody, an adjuvant comprising the antibody, a method of detecting a cell expressing HSP90 on the... Agent: Riken

20110280880 - Prevention, treatment and diagnosis of p.gingivalis infection: The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.... Agent:

20110280884 - Anti-cd98 antibody: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to... Agent: Kirin Pharma Kabushiki Kaisha

20110280883 - Fully human anti-epidermal growth factor receptor antibodies: Disclosed are fully human anti-epidermal growth factor receptor (EGFR) antibodies, fragments thereof, and nucleic acid sequences encoding for the same. Further disclosed are methods of making and using the antibodies.... Agent: Samsung Electronics Co., Ltd.

20110280885 - Cancer immunotherapy: A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an... Agent: The Penn State Research Foundation

20110280887 - Methods for diagnosis of cardiovascular disease: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.... Agent: The Brigham & Women's Hospital, Inc.

20110280886 - Treating cancer by modulating mnk: The present invention relates to a method for treating cancer in a subject using a mTOR inhibitor in combination with a therapeutically effective amount of a modulator of a MNK.... Agent: Novartis Forschungsstiftung, Zweigniederlassung, F Riedrich Miescher Institute For Biomedical Resear

20110280888 - Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.... Agent: Bioalliance C.v.

20110280889 - High affinity t cell receptor and use thereof: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.... Agent:

20110280890 - Prodrugs of cc-1065 analogs: The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or... Agent: Immunogen, Inc.

20110280891 - Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.... Agent:

20110280892 - Toxin conjugated eph receptor antibodies: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.... Agent: Seattle Genetics, Inc.

20110280894 - Her2/neu specific t cell receptors: The present invention is directed to T cell receptors (TCR) recognizing antigenic peptides derived from Her2/neu, in particular peptide 369, and being capable of inducing peptide specific killing of a target cell overexpressing HER2/neu. The present invention is further directed to an antigen specific T cell, comprising said TCR, to... Agent:

20110280895 - Immunotherapeutic method using allo-cells which co-express cd1d and target antigen: e

20110280893 - Synthetic lipid a derivative: The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative.... Agent: University Of Georgia Reseach Foundation, Inc

20110280898 - Inhbb epitope peptides and vaccines containing the same: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from INHBB that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as... Agent: Oncotherapy Science, Inc.

20110280896 - Methods and compositions for tumor vaccination and therapy: The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I... Agent:

20110280897 - Polypeptides and uses thereof: The invention provides a polypeptide having a sequence comprising from 10 to 24 consecutive amino acids from residues 215-233 of the sequence of human cyclin B1 protein or homolog thereof, as well as a nucleic acid molecule encoding the polypeptide, and compositions thereof. The invention also provides a method for... Agent: University Of Pittsburgh-of The Commonwealth System Of Higher Education

20110280899 - Novel immunogenic lipopeptides comprising t-helper and cytotoxic t-lymphocyte (ctl) epitopes: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides... Agent: The Council Of The Queensland Institute Of Medical Research

20110280900 - Clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide: The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of Clostridium chauvoei that represents the major cytotoxic activity of C. chauvoei. This toxin confers C. chauvoei its characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis by... Agent:

20110280901 - Diagnosis and treatment of trypanosoma cruzi infection and chagas disease: Provided herein are vaccine compositions for control of Trypanosoma cruzi infection and Chagas disease. The compositions comprise plasmids encoding o GPI-anchored genes ASP-2, TcG-1, TcG2 and TcG4 from Trypanosoma cruzi; plasmids encoding cytokines IL12 and GM-CSF; and plasmids encoding a gene expression system. Certain vaccine compositions comprise recombinant proteins, selected... Agent:

20110280902 - Compounds and methods for diagnosis and treatment of leishmaniasis: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of... Agent: Infectious Disease Research Institute

20110280903 - Immunostimulatory combinations: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.... Agent:

20110280904 - Generation of virus-like particles and use as panfilovirus vaccine: In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburs with lipid rafts during assembly and budding, and the requirement of functional rafts for... Agent:

20110280905 - Live attenuated chimeric porcine circovirus vaccine: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in... Agent: Virginia Tech Intellectual Properties, Inc.

20110280906 - Method for augmenting the immunogenicity of an antigen: The present invention relates to a method for augmenting the immunogenicity of an antigen in a mammal, comprising immunizing the mammal with a composition comprising the antigen, and an adjuvant in an amount of effective to augment the immunogenicity of said antigen, wherein the adjuvant comprises a Ling-Zhi-8 (LZ-8) protein.... Agent: Yeastern Biotech Co., Ltd

20110280907 - Method and system for building a phylogeny from genetic sequences and using the same for recommendation of vaccine strain candidates for the influenza virus: A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without... Agent: Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

20110280908 - Multimeric protein toxins to target cells having multiple identifying characteristics: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.... Agent: The Government Of The United States, As Represented By The Secretary Of Health And Human

20110280909 - Method and system for effecting changes in pigmented tissue: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.... Agent:

20110280910 - Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis: The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane bound or soluble IgD, to an immunogenic or... Agent: Arne Forsgren Et Al.

20110280911 - Cancer vaccine compositions and methods of using the same: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions... Agent: The Regents Of The University Of Michigan

20110280912 - Degradable polymer nanostructure materials: This invention relates generally to composites comprising a plurality of nanostructures, and methods of making the same. In some embodiments, the composites further comprise a polymer. In some embodiments, the composites may have desirable properties such as, for example, biodegradability, biocompatibility, and/or high tensile strength. In one embodiment, the plurality... Agent: Massachusetts Institute Of Technology

20110280915 - Encapsulation of pancreatic cells derived from human pluripotent stem cells: The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.... Agent:

20110280914 - Hydrogels crosslinked with gold nanoparticles and methods of making and using thereof: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells.... Agent: University Of Utah Research Foundation

20110280913 - Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders: Methods and compositions for treating and/or diagnosing a B-cell malignancy are described.... Agent: The Ohio State University

20110280917 - Resorbable thin membranes: Resorbable lactide polymer thin membranes are disclosed. The thin membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between... Agent: Mast Biosurgery Ag

20110280916 - Stable hydroalcoholic oral spray formulations and methods: Stable formulations of an active pharmaceutical agent suitable for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration of active pharmaceutical agent formulations are provided. Preferred embodiments of the invention provide formulations comprising an active pharmaceutical agent, a solvent, a buffer, and a... Agent:

20110280918 - Composition comprising phospholipids in combination with ascorbic acid and cosmetic products comprising it: A paste composition comprising at least 25% phospholipids by weight in combination with at least 0.5% ascorbic acid by weight and a cosmetic product comprising this paste and a cosmetically acceptable carrier.... Agent: L. Raphael Sa

20110280919 - Reinforced absorbable synthethic matrix for hemostatic applications: The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone.... Agent:

20110280920 - Peptides and compositions for prevention of cell adhesion and methods of using same: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ... Agent: Tel Hashomer Medical Research Infrastructure And Services Ltd.

20110280921 - Antibacterial hydrogel and use thereof in orthopedics: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention... Agent: Mero S.r.l

20110280922 - Devices and methods for treating and/or preventing diseases: The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. a peptide such as leuprolide, via the vagina to a female mammal. In some embodiments, the invention also relates to methods for the treatment of obesity and eating disorders, diabetes, multiple sclerosis (MS), endometriosis, uterine fibroids,... Agent: Combinent Biomedical Systems, Inc.

20110280923 - Bolus devices for the delivery of active agents to animals: A bolus for administration of a substance to an animal, the bolus including An external coating, and A core inside the external coating wherein the core is formed from a plurality of dosage media, wherein each dosage media contains a substance, the bolus characterised in that the dosage media are... Agent: Bomac Research Limited

20110280924 - Biodegradable filler for restoration of alveolar bones: A biodegradable filler for restoration of alveolar bones is disclosed, which includes: first cross-linked collagen fibers prepared from reacting Non-crosslinked collagen fibers with a cross-linking agent; and supporting particles which are biomedical ceramic particles, bioactive glass, or a combination thereof, and distributed among the first cross-linked collagen fibers.... Agent: Sunmax Biotechnology Co., Ltd.

20110280925 - Dual and single layer dosage forms: Provided is a dual-release, dual-adhesiveness flexible thin film dosage form comprising: a quick-release subfilm comprising an admixture of polymer, which comprises predominantly highly water-soluble polymer(s), and a bioactive agent, the polymers and other components of the quick-release subfilm adapted to provide 20 minute or less erodibility for the quick-release subfilm;... Agent: Bionex Pharmaceuticals LLC

20110280927 - Composition and dressing with nitric oxide: A dressing composition for use as a skin dressing comprises an elastomeric-adhesive composition, and a zeolite comprising releasably adsorbed nitric oxide. The zeolite may comprise a transition metal cation such as Co, Fe, Mn, Ni, Cu, Zn, Ag or a mixture thereof as an extra-framework metal cation, preferably Zn. The... Agent: Pq Silicas Uk Limited

20110280928 - Wound care device having fluid transfer properties: This disclosure relates to wound care devices which are capable of one-way, directional flow of fluids and contaminants away from the wound site to the opposite side of the wound care device, which functions as a fluid reservoir. This fluid transport mechanism generally aids in reducing wound maceration by removing... Agent:

20110280926 - Wound dressing: i

20110280933 - Epicatechin compositions and methods: Provided herein are methods and compositions for treating a subject who has pulmonary damage or an injury caused by or who is at risk for an injury caused by an anti-vesicant agent. The compositions comprise cacao extracts that include a mixture of epicatechin and one or more epicatechin oligomers and... Agent: Cacao Bio-technologies, LLC

20110280934 - Increased expression of specific antigens: The response of immunotherapy in the treatment of cancer is enhanced by use of an oligonucleotide in a dose effective to induce at least one of endogenous production of cytokines, and the regulation of the expression of one or more of the cell surface antigens (FIG. 1).... Agent:

20110280931 - Matrix metalloproteinase inhibitor: Whereby R or R1, S or S1 is a Carbon, Nitrogen or Sulfur atom Z or Z1 and B or B1 is independently H or an alkyl, amino acid residue or amide thereof. Alternatively, Z or Z1 and B or B1 may constitute an fused, unsubstituted, cyclic ring structure, a... Agent:

20110280930 - Products and methods for stimulating an immune response: The present invention provides products which comprise (i) a support and (ii) a BCR-binding antigen attached to the support. The products are capable of BCR-mediated internalization. The products are useful in the induction or augmentation of immune responses, and methods and uses of the products are provided. The present invention... Agent:

20110280929 - Sirna of nf-kb p105 for inhibiting cell proliferation and migration and a composition comprising same: The present invention relates to a siRNA which targets mRNA of the NF-Kappa B p105 gene to cause its degradation by RNAi induction. In addition, the present invention provides a pharmaceutical composition for the treatment of diseases associated with aberrant cell proliferation and migration, comprising the siRNA and delivery vehicle... Agent:

20110280932 - Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are... Agent: Pacira Pharmaceuticals, Inc.

20110280935 - Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology.... Agent:

20110280937 - Hard capsule: The object of the invention is to provide a hard capsule that is excellent in stability even when filled with a solvent for dissolving a poorly soluble pharmaceutical active ingredient, and that has excellent mechanical strength in a low-humidity environment. The invention provides a hard capsule having a film containing... Agent: Nisshin Kasei Co., Ltd.

20110280936 - Self breaking tablets: Self-breaking tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. Methods for production of these formulations and tablets and their administration are also provided.... Agent: Aptapharma, Inc.

20110280938 - Sustained release pharmaceutical composition of quetiapine and process for preparation thereof: The present invention relates to sustained release pharmaceutical composition of quetiapine, and process for preparing such composition. More particularly, it relates to sustained release pharmaceutical composition of quetiapine comprising a non gelling agents such as carrageenan and pharmaceutically acceptable excipients.... Agent: Torrent Pharmaceuticals Limited

20110280939 - Oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride: The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a pseudoephedrine-hydrochloride layer coated outside the nucleus with a coating solution composed of pseudoephedrine hydrochloride, a binder, a lubricant and pure water/alcohol, a release-control layer... Agent: Everest Pharm. Industrial Co., Ltd.

20110280941 - Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes: The present invention relates to compositions, kits and methods of treating diabetes. More specifically, compositions of at least one proton pump inhibitor and at least one insulin secretagogue, kits and methods of their use to treat diabetes.... Agent: Mefford Scientific, LLC

20110280940 - Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy: The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.... Agent:

20110280942 - Film coating composition and methods of making and using the same: A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to... Agent:

20110280943 - Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same: Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications.... Agent:

20110280944 - Fibrous microcapsules and methods of assembly and use thereof: The present invention relates to assembly of peptide amphiphiles and biopolymers into fibrous microcapsules, and uses thereof. In particular, the present invention provides devices, compositions, and methods for interfacial self-assembly of peptide amphiphiles and biopolyments into fibrous microcapsules, and uses thereof.... Agent:

20110280945 - Novel method for the preparation of granulates of active constituents, and granulates as obtained: The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.... Agent: Debregeas Et Associes Pharma

20110280946 - Surface-treating agents, surface-treated powders, and cosmetics comprising the same: e

20110280947 - Embolization: A particle includes a ferromagnetic material, a radiopaque material, and/or an MRI-visible material.... Agent: Boston Scimed Place

20110280948 - Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins: The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium... Agent: Alltech, Inc.

20110280949 - Microparticles for use in immunogenic compositions: Immunogenic compositions are disclosed which comprise microparticles that comprise a biodegradable polymer, an immunological adjuvant and a tocol-family compound. Methods of making and using such microparticle compositions are also disclosed.... Agent:

20110280951 - Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome: The invention relates pharmaceutical/dietary supplement/food ingredient(s) selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Sphaeranthus indicus and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Garcinia mangostana. The... Agent: Laila Nutraceuticals

20110280950 - Synergistic antioxidant compositions: Antioxidant compositions for the stabilization of fat sources against oxidation, stabilized fat source compositions, and methods of stabilizing fat sources against oxidation are described. In particular, an antioxidant emulsion that includes quercetin in addition to at least one other ingredient and a lipid carrier is described.... Agent: Novus International Inc.

20110280952 - Platelet lysate and bioadhesive compositions thereof for the treatment of mucositis: The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described.... Agent: Universita' Degli Studi Di Pavia

20110280953 - Compositions and methods for altering stool quality in an animal: The present invention provides compositions and methods for improving stool quality of a puppy by adjusting the balance of metabolizable cations to metabolizable anions consumed by the puppy.... Agent: Hill's Pet Nutrition, Inc.

20110280954 - Compositions and methods for altering stool quality in an animal: The present invention provides compositions and methods for improving stool quality of a puppy by adjusting the balance of metabolizable cations to metabolizable anions consumed by the puppy.... Agent: Hill's Pet Nutrition, Inc.

20110280955 - Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health: A nutritional supplement for adults fifty years and older, and methods of use thereof, are provided that are designed to be most effective in optimizing health, improving vitality and immunity, and improving, aiding, eye and bone health.... Agent: Wyeth LLC

20110280956 - Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or... Agent: Spectrum Pharmaceuticals, Inc.

20110280957 - Use of finely dispersed metal particles in a material, a skin patch and an orthopedic article: The invention relates to a material which is provided for use in direct contact with the skin of a user and which contains a percentage in silver that is finely dispersed in said material. The material is provided with a content in another metal that is finely dispersed in the... Agent: Otto Bock Healthcare Gmbh

20110280958 - Active compound combinations: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a metal salt (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of... Agent: Bayer Cropscience Ag

20110280959 - Fungicidal composition and method for controlling plant diseases: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n... Agent: Ishihara Sangyo Kaisha, Ltd.

20110280961 - Synergistic antimicrobial mixtures: A broad spectrum antimicrobial composition consisting essentially of an iodopropynyl compound in combination with a benzimidazole and a metal borate is disclosed. The composition can be used to protect industrial systems against microbial growth and, more particularly, to protect substrates such as paints, coatings, stucco, concrete, stone, cementaceous surfaces, wood,... Agent:

20110280960 - Thick pine needle extract composition for capsulation: The invention relates to pharmaceutics and to the pharmaceutical and food industries, in particular, to the production of compositions for stimulating the mucous membrane, ameliorating skin integument, and enhancing the organism's immunity. The aim of the invention is to develop a compound containing a thick pine needle extract with an... Agent:

20110280962 - Metallization device and method: e

20110280963 - Combination therapy for the treatment of cancer: The present invention provides methods of sensitizing lung cancer cells to cisplatin and inhibiting the growth of lung cancer tumors by employing a modified eIF-4E antisense oligonucleotide and cisplatin in combination.... Agent: Isis Pharmaceuticals, Inc.

20110280964 - Composition and method of treating hearing loss: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen,... Agent: The Regents Of The University Of Michigan

20110280965 - Materials and methods of using calcium for reduction of inflammation: Nutritional approaches for the control of inflammation can involve the administration of therapeutic amounts of calcium. The administration of appropriate amounts of calcium to an individual results in a reduction in inflammatory processes and markers associated with the inflammatory processes. The therapeutic amount of calcium can be selected to change... Agent:

20110280966 - Dosing regimens and methods of treatment using carbon monoxide: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.... Agent: Ikaria

20110280967 - Disintegrable formulations of lanthanum carbonate: Disintegrable preparations of lanthanum carbonate prepared by co-precipitation, facilitating the manufacture of oral pharmaceutical dosage forms such as tablets, capsules, powders, granules, and sprinkles, and the use of such dosage forms to treat subjects with hyperphosphatemia are disclosed.... Agent: Mylan Inc.

20110280968 - Natural extract containing xanthohumol, method for the production thereof and products produced therefrom: The invention relates to a method for producing an extract containing xanthohumol (XN), which is obtained from toasted cereal products, cereal malt, coffee or cocoa. The XN-content in said extract is in the region of 10 mg/kg-2 g/kg xanthohumol. The use of XN-toasted extracts enables the XN-content of foodstuffs and... Agent: Ta-xan Ag

20110280969 - Petroleum-free compositions for skin care and other applications, and methods of making same: A substantially non-aqueous, aerated composition is free of petroleum-based components and is suitable for skin applications. The composition primarily includes wax and oil, and can further include vitamin E oil and an essential oil. The composition can be a semi-solid at room temperature. A method of making the composition includes... Agent: Waxelene, Inc.

20110280970 - Absorbable putty-like implants and methods for their use for mechanical hemostasis of bone and for the treatment of osseous defects: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered, carboxylic acid salt, a liquid block copolymer of ethylene oxide and propylene oxide, and a tocopherol.... Agent: Orthocon, Inc.

20110280971 - Berry oils and products: The invention includes embodiments of berry oils, cold pressed, and products incorporating the berry oils.... Agent:

20110280972 - Preparation for the treatment of tinnitus: The invention relates to the use of blueberry extract for the preparation of a therapeutic composition for oral administration for the treatment and prevention of tinnitus.... Agent:

20110280973 - Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport: Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not... Agent: Fhg Corporation D/b/a Integrity Nutraceuticals

20110280975 - Composition comprising bamboo extract and the compounds isolated therefrom showing activity for the treatment and prevention of inflammatory and blood circulation disease: The extracts from bamboo plant have potent anti-inflammatory activity by inhibiting NO production and circulation-improving activity by inhibiting elastase activity and, healing the wound of vascular endothelial cell, activating u-PA expression and inhibiting PAI-1 expression, lowering cholesterol deposit and inhibiting neointima formation, therefore it can be used as the therapeutics... Agent: Unigen, Inc.

20110280974 - Substances having body mass redistribution properties: There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass... Agent: Horizon Science Pty. Ltd.

20110280976 - Use of gingerols for cancer patients suffering from nausea and emesis induced by chemotherapy: This invention is for an improved method for making enhanced ginger capsules and for using these capsules for treating nausea and emesis in cancer patients.... Agent:

20110280977 - Composition for relieving and preventing hangover and beverage comprising composition: Disclosed is a composition for relieving and preventing hangover and, more specifically, a composition for relieving and preventing hangover, which includes Hovenia dulcis Thunb fruit extract, Rosa Roxburghii extract, Engelgardtia chrysolepis HANCE extract, rotus (Nelumbo nucifera Gaertner fruits) extract and nicotinic acid amide as active ingredients, and accelerates in vivo... Agent:

20110280978 - Cosmetic use of botulinum toxin for the treatment of eyebrow and forehead ptosis, and unwanted eyebrow expression: A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to affect a more desirable appearance. In a broad aspect the invention comprises injecting small quantities of botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles,... Agent:

20110274616 - 4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors: P

20110274617 - Antibody-targeted carrier for contrast agents: A nanoconjugate is formed from a self-assembled unilamellar vesicle (ULV), at least one contrast agent which may be a MRI contrast agent, a radioisotope or a fluorophore, and at least one antibody, which may be an IgG or an antibody fragment such as a single-domain antibody. The nanoconjugate be targetted... Agent: National Research Council Of Canada

20110274619 - Brain tumor targeting peptides and methods: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype... Agent: Arch Cancer Therapeutics, Inc.

20110274618 - Diagnostic and/or therapeutic agent, method for the manufacture thereof and use thereof: The invention relates to the fields of materials sciences and medicine and relates to an agent, which can be used, for example, as a contrast medium for the localization of cancer cells. The object of the present invention is to disclose an agent which sensitively and selectively recognizes the site... Agent: Leibniz-institut Fuer Festkoerper-und Werkstoffforschung Dresden E.v.

20110274621 - Active particles for bio-analytical applications and methods for their preparation: Nanoparticles, which are luminescent and/or electroactive and/or suitable for MRI (magnetic resonance imaging and/or PET (positron emission tomography) applications, comprise a micelle, which has a hydrophilic shell and an hydrophobic central portion, and a polysilicate core; the micelle comprises a plurality of molecules of a functionalized surfactant having the following... Agent: Alma Mater Studiorum-universita'di Bologna

20110274620 - Multifunctional degradable nanoparticles with control over size and functionalities: In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically,... Agent:

20110274622 - Nanocrystal nano-emulsion:

20110274623 - Stabilized fibronectin domain compositions, methods and uses: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability... Agent:

20110274624 - Contrast agents in porous particles: MRI imaging compositions are disclosed comprising non-chelated MRI contrast agents in the pores of at least one porous microparticle or nanoparticle. The compositions of the invention have been found to exhibit increased relaxivity and therefore, enhanced MRI imaging. The non-chelated contrast agents include T1 contrast agents, such as those including... Agent: Board Of Regents Of The University Of Texas System

20110274625 - Liposomal composition for convection-enhanced delivery to the central nervous centre: Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous centre thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent... Agent: Medgenesis Therapeutix ,inc.

20110274626 - Pulse sequencing with hyperpolarisable nuclei: There is described a method of selective observation of non-hydrogenative para-hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)]+, and analogues thereof, for use in a PHIP magnetic resonance technique and a... Agent: University Of York

20110274627 - Method of making an aerosol shave composition comprising a hydrophobical agent forming at least one microdroplet: A process of making an aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicon, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns.... Agent:

20110274628 - Nicotine-containing pharmaceutical compositions: A composition intended to be employed for therapeutic purposes incorporates nicotine and at least one other nicotinic compound. Representative forms of nicotine can be as a free base (e.g., as a mixture of nicotine and microcrystalline cellulose), as a form of nicotine salt (e.g., as nicotine bitartrate) or as nicotine... Agent:

20110274629 - Natural polymer blends for use in personal care products: Embodiments of the present description provide a blend for use in a personal care product having a modified xanthan gum and a galactomannan, wherein the modified xanthan gum is a non-pyruvylated xanthan gum, and the modified xanthan gum and the galactomannan are present in the blend in a ratio from... Agent: Cp Kelco U.s., Inc.

20110274630 - Methods and compositions for extracting flavor and fragrance compounds and solubilizing essential oils: Provided are methods for extracting flavor and fragrance materials from natural plant materials, using poly(trimethylene ether) glycol homopolymers and copolymers. The poly(trimethylene ether) glycol homopolymers and copolymers act as solubilizers for essential oils, and can be used to provide compositions having a variety of uses in applications such as cosmetics,... Agent: E. I. Du Pont De Nemours And Company

20110274631 - Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Galderma S.a.

20110274632 - Sunscreen cosmetic: a

20110274634 - Alkyl ketal esters as dispersants and slip agents for particulate solids, methods of manufacture, and uses thereof: wherein a is 0 or an integer of 1 to 12, specifically 1 to 6, more specifically 1 to 4; b is 0 or 1; R2 is a divalent C1-8 group optionally substituted with up to 5 hydroxyl groups; and R1 is C1-6 alkyl, and wherein at least a portion... Agent: Segetis, Inc.

20110274633 - Compositions and methods for uv-curable cosmetic nail coatings: The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions that provide improved adhesion-promoting and improved solvent-susceptibility.... Agent: Colomer Usa

20110274635 - Whitening composition for external skin application containing oldenlandia diffusa willd, rheum undulatum, and broussonetia kazinoki extract: Disclosed is a whitening composition for external skin application. Containing one or more of Oldenlandia diffusa Willd extract, Rheum undulatum extract and Broussonetia kazinoki extract as an effective ingredient, the whitening composition for external skin application exhibits superior melanogenesis inhibition and skin whitening effect. Accordingly, it may be used in... Agent: Amorepacific Corporation

20110274636 - Compositions containing acrylic thickener and high viscosity non-silicone oil: The invention relates to a composition, especially a cosmetic composition, comprising at least one acrylic thickener and at least one high viscosity non-silicone oil, as well as to methods of using such compositions.... Agent: L'or&#xe9 Al S.a.

20110274637 - Ethylene oxide free antiperspirant/deodorant formulations: This invention relates to ethylene oxide free antiperspirant/deodorant formulations comprising at least one antiperspirant/deodorant active ingredient and at least one quaternary polymer having the INCI designation polyquaternium 37.... Agent: CognisIPManagement Gmbh

20110274638 - Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics: i

20110274640 - Hair treatment agents having low-dose oligopeptides:

20110274641 - Non-petrochemically derived cationic emulsifiers that are neutralized amino acid esters and related compositions and methods: wherein R1 is an alkyl group; R2 is a linear or branched carbon chain; and the amine group of the amino acid is neutralized with an acid. The composition is substantially free of petrochemicals and/or derivatives of petrochemical materials. The aqueous phase and the non-aqueous phase are emulsified by the... Agent: Inolex Investment Corporation

20110274642 - Hair cosmetic: e

20110274639 - Peptide-based coloring reagents for personal care: Peptide-based coloring reagents are described in which a body surface-binding peptide is covalently attached to a pigment, the surface of which is coated with a layer containing at least 3 atom percent of silicon. The peptide-based coloring reagents are useful for coloring body surfaces such as hair, skin, nails, and... Agent: E. I. Du Pont De Nemours And Company

20110274643 - Fragrant formulations, methods of manufacture thereof and articles comprising the same: Disclosed herein is a fragrant formulation comprising a fragrant composition, and an alkyl ketal ester. Disclosed herein too are methods for manufacturing the fragrant formulation.... Agent: Segetis, Inc.

20110274644 - Lens care compositions: The present invention provides a lens care composition having a persistent lipid removal efficacy characterized by that the amount of lipids adsorbed by a silicone hydrogel lens after about 10 cycles of soiling with a lipid soiling solution and subsequent cleaning with a lens care solution of the invention under... Agent:

20110274645 - Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods: Methods of performing medical procedures, and methods of making bone-growth-promoting compositions useful in performing medical procedures are provided. Apparatus useful both in methods of performing medical procedures, and in methods of making bone-growth-promoting compositions useful in performing medical procedures, are provided. The bone-growth-promoting compositions made according to the disclosed methods... Agent: Doctor's Research Group, Inc., A Connecticut Corporation

20110274646 - Compounds and combinations: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination... Agent: Suomen Punainen Risti Veripalvelu

20110274650 - Compositions and methods of treating inflammatory and autoimmune diseases: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.... Agent: Amgen Inc.

20110274648 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Bristol-myers Squibb Company

20110274647 - Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy: The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.... Agent: Yeda Research And Development Co., Ltd.

20110274649 - T-cell vaccination with viral vectors via mechanical epidermal disruption: Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The... Agent: The Brigham And Women's Hospital, Inc.

20110274652 - Methods for treating hepatitis c virus infection: A method of treating a patient infected with HCV comprises administering to the patient VX-950 and interferon. In the method, an interferon trough level and/or a VX-950 trough level of the patient independently are monitored. The method further includes determining whether or not to adjust: subsequent administration of VX-950 to... Agent: Vertex Pharmaceuticals Incorporated

20110274651 - Noscapine and noscapine analogs and their use in treating infectious diseases by tubulin binding inhibition: Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by... Agent: Emory University

20110274653 - Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells: Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific... Agent: Baylor Research Institute

20110274656 - Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C... Agent: B&c Biopharm Co., Ltd.

20110274655 - Tetrazolones as inhibitors of fatty acid synthase: e

20110274654 - Triazoles as inhibitors of fatty acid synthase:

20110274657 - Oxadiazole derivatives as s1p1 receptor antagonists: The present disclosure relates to oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptor.... Agent:

20110274658 - Chimeric activators: quantitatively designed protein therapeutics and uses thereof: Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein... Agent: President And Fellows Of Harvard College

20110274659 - Biological control agent for plants: A biological control agent for plants and a method of inoculating the plants with the biological control agent in order protect against plant disease are provided. The treatment method consists of inoculating the plant with a strain of cucumber mosaic virus (CMV), referred to as the KU1 strain, having an... Agent:

20110274660 - Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes: The invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria... Agent:

20110274671 - Human progenitor t-cells: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem... Agent:

20110274670 - Mesenchymal stem cells which express human hepatic growth factor,manufacturing method thereof, and use thereof as therapeutic agent for liver diseases: The present invention relates to adult stem cells and a manufacturing method thereof. More specifically, the present invention relates to a recombinant expression vector containing a human hepatic growth factor (hHGF) gene, mesenchymal stem cells which are transformed thereby and express the hHGF, a manufacturing method of the mesenchymal stem... Agent:

20110274669 - Therapeutic retroviral vectors for gene therapy: Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.... Agent:

20110274672 - Sialic acid producing bacteria: The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid.... Agent: Nestec S.a.

20110274673 - Bacillus amyloliquefaciens strain: The present disclosure relates to a strain of Bacillus amyloliquefaciens bacteria that hyperproduces amylase enzyme and protease enzyme. The strain is also suitable for producing lipase for the degradation of oleaginous materials such as fats, greases and cooking oils. The strain also has excellent fungicidal and/or fungistatic qualities. The strain... Agent: Novozymes Biologicals, Inc.

20110274676 - Topical use of probiotic bacillus spores to prevent or control microbial infections: Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include... Agent:

20110274661 - Attentuated herpesvirus encoding a mek pathway polypeptide: The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that... Agent: The University Of Chicago

20110274665 - Dosage unit formulations of autologous dermal fibroblasts: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved... Agent: Fibrocell Science, Inc.

20110274664 - Hepatic progenitor cells and uses thereof: Disclosed are cells, compositions, and methods for treating liver diseases.... Agent:

20110274666 - Method of engrafting cells from solid tissues: A method of repairing diseased or dysfunctional organs or of establishing a model system of a disease state is provided. For repairing diseased organs, the method involves engraftment of cells from healthy tissue of the diseased or dysfunctional organ admixed with gel-forming biomaterials and nutrient medium, signaling molecules and extracellular... Agent: University Of North Carolina At Chapel Hill

20110274667 - Methods for obtaining cell populations from adipose tissue: Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating... Agent: Baxter International Inc.

20110274662 - Methods of producing rpe cells and compositions of rpe cells: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from... Agent:

20110274663 - Pharmaceutical composition containing human mesenchymal stem cell: Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order:... Agent: Jcr Pharmaceuticals Co., Ltd.

20110274668 - Volume maintaining osteoinductive/osteoconductive compositions: An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a... Agent: Warsaw Orthopedic, Inc.

20110274674 - Ischemic tissue cell therapy: The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual... Agent: Universidade Federal De Sao Paulo - Unifesp

20110274675 - Therapeutically useful molecules: A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarily determining regions (CDRs): CDR1α: SSYSPS CDR2α: YTSAATL CDR3α: VVSPFSGGGADGLT or comprising or consisting of SPPSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs):... Agent: Imperial Innovations Limited

20110274678 - Beverage: A nutritional beverage composition for providing nutrition to a patient suffering from a kidney ailment comprises a flavor component and a natural sweetener, and is further characterized in that it does not contain amounts of particular ingredients that may not be desirable in treating kidney ailments. In one embodiment of... Agent:

20110274677 - Biological pest control mixture containing d-limonene and nutmeg oil: An organic pest control product comprising nutmeg oil and D-limonene is disclosed. In some embodiments the organic pest control product further comprises a miscibility enhancer to enhance the effectiveness of the product. In some embodiments the miscibility enhancer can comprise a liquid soap or detergent. Additional formulations that comprise cassia... Agent:

20110274679 - Compositions and methods of sirt activation: Compositions and methods of SIRT activation are presented in which one or more vitamin compounds, and especially vitamin B compounds are used to significantly increase SIRT activity in vitro and in vivo. In especially preferred compositions, vitamin B6, vitamin B12, and vitamin B2 are present in synergistic quantities.... Agent: Vdf Futureceuticals, Inc.

20110274680 - Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases: Synergistic chemical compositions of bioactive compounds in a dietary supplement for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases; chemical compositions of a sugar free super sweetener for people with Type-2 Diabetes disease and a targeted nano delivery of bioactive compounds and/or bioactive molecules are described. Furthermore, microelectro-mechanical system... Agent:

20110274681 - Human e3alpha ubiquitin ligase family: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these... Agent: Amgen Inc.

20110274682 - Methods for protease assisted protein delivery: A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis.... Agent: The Regents Of The University Of California

20110274683 - Antibodies that bind csf1r: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are... Agent: Five Prime Therapeutics, Inc.

20110274684 - Cytotoxic antibodies directed against antibodies inhibiting factor viii: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70%... Agent: Lfb Biotechnologies

20110274685 - Antibodies that bind human cd27 and uses thereof: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.... Agent: Celldex Therapeutics Inc.

20110274686 - Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and melphalan.... Agent: Sanofi-aventis

20110274687 - Methods of treating tslp-related inflammatory disorders: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and... Agent: Amgen Inc.

20110274688 - Prevention of tumors with monoclonal antibodies against neu: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its... Agent: The Trustees Of The University Of Pennsylvania

20110274689 - Compounds and methods to measure metabolic function and restore normal metabolic function: The invention relates to treatment to restore normal metabolic function, including but not limited to normal glucose levels. The invention in one embodiment contemplates methods of reducing elevated glucose levels in subjects with elevated glucose levels by administering a composition comprising at least a portion of human Sfrp5. The invention... Agent:

20110274690 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent:

20110274694 - Erk1/2 posphorylation site specific antibody: The invention relates to an antibody specific to Erk1/2 phosphorylated at Thr188 and a method for producing the same. The invention also relates to an in vitro method for determining the presence of phosphorylated Erk1/2 in a sample using the antibody of the invention. Therefore, the invention also comprises an... Agent:

20110274691 - Ferroportin antibodies and methods of use: Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.... Agent: Amgen Inc.

20110274692 - Screening methods: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of... Agent: Xoma Technology Ltd.

20110274693 - Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof: Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or... Agent: New York University

20110274695 - Prodrugs containing novel bio-cleavable linkers: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of... Agent: Apparao Satyam

20110274696 - Antibodies to ccr2: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof.... Agent: Pfizer Inc.

20110274697 - Novel uses: The present invention relates generally to the use of bendamustine in combination with an anti-CD20 antibody to treat cancer.... Agent:

20110274698 - Immunomodulation of inflammatory conditions utilizing follistatin-like protein-1 and agents that bind thereto: Follistatin-like protein (FSTL-1) is a secreted glycoprotein of unknown function, first isolated from mouse osteoblastic cells as a transforming growth factor-β1-inducible gene. The inventors have discovered that FSTL-1 is a proinflammatory mediator. As such, the invention provides for composition and methods of using agents that bind to FSTL-1 to modulate... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20110274699 - Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.... Agent:

20110274700 - Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express... Agent: The Brigham And Women's Hospital, Inc.

20110274701 - Composition and method for preventing/decreasing respiratory illness: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is... Agent: Camas Incorporated

20110274702 - Neutralizing anti-influenza a virus antibodies and uses thereof: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode,... Agent: Institute For Research In Biomedicine

20110274703 - Detection and treatment of non-dermal fibrosis: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.... Agent: The Brigham And Women's Hospital, Inc.

20110274704 - Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with... Agent: Immunomedics, Inc.

20110274705 - Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells: The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective... Agent:

20110274707 - Composition for improving inflammatory disease using abh antigens: The present invention relates to a composition for improving inflammatory disease, and more specifically to a composition for improving inflammatory disease able to improve inflammatory reactions and the barrier function of epithelial tissue such as the skin, to enhance aging resistance and skin elasticity and to prevent or treat aging.... Agent: Snu R&db Foundation

20110274706 - Nucleic acid delivery vehicle and uses thereof: A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles further comprises one or more signal peptides attached to the nanoparticles. The nanoparticles and the nucleic acids are agglomerated to... Agent: General Electric Company

20110274708 - Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling: The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the... Agent: Cedars-sinai Medical Center

20110274709 - T-cell immunogens derived from anti-viral proteins and methods of using same: Isolated polypeptides related to endogenous anti-viral polypeptides; and compositions, including immunogenic compositions, comprising a subject isolated polypeptide are disclosed herein. A subject isolated polypeptide comprises an amino acid sequence having substantial amino acid sequence identity to a contiguous stretch of amino acids of one or more endogenous anti-viral polypeptides, wherein... Agent:

20110274710 - Pcv2 immunogenic compositions and methods of producing such compositions: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading... Agent: Boehringer Ingelheim Vetmedica, Inc.

20110274711 - Hla-g polypeptides and pharmaceutical uses thereof: The present invention relates to novel proteins and pharmaceutical uses thereof The invention more specifically relates to novel proteins comprising the sequence of an HLA-5 antigen fused to the sequence of a b2 microglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as... Agent: Hla-g Technologies

20110274712 - Antigenic compositions: The invention relates to antigenic compositions and to methods for immunising animals using same. The antigenic compositions comprises a lipid formulation most usually in solid form, and at least one antigenic component. A preferred antigenic component is a living organism. In a preferred embodiment the composition is formulated for oral... Agent:

20110274713 - Antigen-presenting scaffolds: The invention relates to compounds having formula (I): Scaffold-[L-(Antigen)t]y (I) wherein Antigen represents at least a portion of a target antigen for modulating an immune response; wherein t is 0 or an integer of at least 1; wherein y is at least 1; wherein the number of Antigens on the... Agent: The University Of Queensland

20110274714 - Broad spectrum vaccine against non-typhoidal salmonella: The present invention is drawn to attenuated Salmonella serovar strains S. Typhimurium and S. Enteritidis, conjugate vaccines derived from these attenuated strains of S. Typhimurium and S. Enteritidis, comprising an O polysaccharide covalently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering... Agent: University Of Maryland, Baltimore

20110274716 - Compositions containing fucoxanthin extract: A composition comprises extract of fucoxanthin, wherein said composition further comprises tocotrienols and/or fucoidan. Said composition can be used to treat obesity. Said composition shows outstanding effect of weight loss. There is outstanding synergy effect among those constituents of the composition.... Agent: Beijing Gingko Group Biological Technology Co., Ltd.

20110274715 - Methods and compositions for cooling the human body: Cooling of the human body is accomplished by topical application of a treatment composition including an extract of a green marine algae. A preferred green marine algae is enteromorpha compressa.... Agent:

20110274717 - Polysaccharide conjugation with detoxified e. coli heat labile enterotoxin (lt) used as vaccine: A detoxified recombinant E. coli heat-labile enterotoxin mutant, LTS61K, is employed as a carrier protein to conjugate polysaccharide. The LTS61K contains a mutated mature sub-unit A (LTA) that includes lysine at amino acid position 61 and a wild-type mature sub-unit B (LTB). Various types of bacterial capsular polysaccharide antigens were... Agent: Development Center For Biotech

20110274718 - System for modulating expression of hypothalmic brain-derived neurotrophic factor (bdnf): Methods for treating tumor associated diseases by administering a nucleic acid sequence encoding brain derived neurotrophic factor (BDNF) where the expression reduces the symptoms of the disease and compositions for mediation of enrichment-induced tumor resistance having brain derived neurotrophic factor (BDNF) are disclosed.... Agent: The Ohio State University

20110274719 - Helicobacter system and uses thereof: Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against... Agent:

20110274720 - Capsular gram-positive bacteria bioconjugate vaccines: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods... Agent: Glycovaxyn Ag

20110274721 - Hiv vaccines based on env of multiple clades of hiv: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another... Agent: The U.s.a., As Represented By The Secretary, Department Of Health And Human Services

20110274722 - Food containing a probiotic and an isolated beta-glucan and methods of use thereof: The invention features a food product containing a probiotic and β-glucan isolated from a natural source, methods of treating a disease or disorder by administering the food product, and a package containing separated components of the food product.... Agent:

20110274723 - Cancer immunotherapy and method of treatment: The instant disclosure relates to methods for treating a cancer patient with an active immunotherapeutic, wherein the methods include assessing a patient's pre-existing immunoreactivity to at least one target antigen, choosing an immunotherapeutic regimen based on the level of pre-existing immunoreactivity, and administering an active immunotherapeutic according to the regimen.... Agent: Mannkind Corporation

20110274730 - Biosurfactant composition produced by a new bacillus licheniforms strain, uses and products thereof: New Bacillus licheniformis strain named V9T14 that produces a new biosurfactant composition that is effective against colonization and/or bio film formation from bacteria. The new biosurfactant composition can be used in combination with biocides for preventing formation and/or for eradicating bacteria grown planktonically and/or as a biofilm, preferably on biotic... Agent:

20110274726 - Chitosan foam medical devices and methods: The invention provides a solid foam wound dressing useful for hemorrhage control and wound repair, as well as methods for making such a wound dressing.... Agent: Providence Health System - Oregon

20110274728 - Compositions and methods for alleviating hyposalivation and for providing oral comfort: Various compositions and methods are provided to alleviate one or more symptoms associated with hyposalivation or xerostomia. Preferred compositions and methods employ one or more plant extracts and/or a proanthocyanidin at a concentration effective to reduce or eliminate the symptoms. Especially preferred extracts are isolated from a fruit and/or seed... Agent:

20110274725 - Decomposable biocompatible hydrogels and system and method for using same: Biocompatible, triggerable degradation, polymerizable hydrogels, uses and delivery devices are disclosed. These hydrogels are at least substantially water soluble macromers, having a variety of uses especially for ocular therapy. The macromers include at least one water soluble region, at least one region which is degradable via a triggering event, usually... Agent:

20110274727 - Depigmenting topical compositions and their uses: Depigmenting topical compositions and their uses are described. In particular, the described compositions can provide improved effectiveness in the dermatological treatment of pigmentation, without disadvantages experienced with other known compositions. The described topical compositions can comprise, in a physiologically acceptable medium, from 3% to 10% of rucinol or one of... Agent: Galderma Research & Development

20110274724 - Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide: Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.... Agent: Galderma Research & Development

20110274734 - Functionalized chemically inert polymers for coatings: Provided herein are methods for functionalizing an polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.... Agent: Advanced Cardiovascular Systems, Inc.

20110274729 - Implantable compositions for repairing osteochondral defects: Compositions are described that are suitable for implantation in a human and that contain a scaffold housing cells having an osteocytic phenotype and, attached to the scaffold, cartilage material containing a population of chondrocytes.... Agent:

20110274732 - Medical device loaded with formulation for targeted delivery of biologically active material/s and method of manufacture thereof: The present invention relates to targeted drug delivery of a drug or therapeutic agent through medical devices coated with formulations comprising of therapeutic agent. The coating on medical devices comprises of therapeutic agent(s), affinity vehicle(s) and additives for targeted drug delivery of biologically active material(s). The invention provides a method... Agent: Meril Life Sciences Private Limited

20110274733 - Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same: Embodiments of the present invention provides medical devices comprising poly(hydroxyalkanoates) and agents.... Agent: Advanced Cardiovascular Systems, Inc.

20110274731 - Production method of fine o/w emulsion external preparation: The present invention provides a production method of a fine O/W emulsion external preparation having the emulsion particle size of 50 to 500 nm comprising the steps of: mixing with stirring, at 70 to 80° C., (A) a hydrophilic nonionic surfactant, (B) a linear higher alcohol having 16 or more... Agent: Shiseido Company, Ltd.

20110274735 - Taste potentiator compositions and edible confectionery and chewing gum products containing same: The present invention relates to compositions and edible orally delivered products, such as confectioneries and chewing gum, which include taste potentiators to enhance the perception of active substances contained therein. More specifically, some embodiments provide potentiator compositions, which include at least one active substance and at least one taste potentiator.... Agent:

20110274736 - Methods for producing silver nanoparticles: Methods for producing silver nanoparticles are described. In one aspect, a liquid solution is prepared that contains phenazine-1-carboxylic acid. Silver metal salt is added to the solution to produce multiple silver nanoparticles.... Agent: King Saud University

20110274738 - Functionalized chemically inert polymers for coatings: Provided herein are methods for functionalizing a polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.... Agent: Advanced Cardiovascular Systems, Inc.

20110274737 - Implantable materials having engineered surfaces and method of making same: An implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.... Agent: Palmaz Scientific, Inc.

20110274739 - Methods for governing tissue growth: Resorbable polymer barrier membranes and methods of their applications are disclosed. In a broad embodiment, methods of governing tissue growth, or preventing tissue growth into a certain spatial area, includes the step of forming a spatial barrier with the present resorbable barrier membrane. The barrier membrane separates a tissue-growth area... Agent:

20110274740 - Methods of reducing symptoms in subjects using single dosage forms with tapering release rates: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single... Agent:

20110274741 - Ingestible compositions and processes of preparation: One or more of hydrolysed wheat flour, soluble dietary fibre, prebiotic dietary fibre, polydextrose and soluble corn fibre ate used as basic matrix-forming ingredients in an expanded food product. The matrix-forming ingredients are mixed together with water, plus a whey protein isolate or whey protein concentrate, to increase the protein... Agent:

20110274742 - Cartilage repair systems and applications utilizing a glycosaminoglycan mimic: The present invention relates to hydrogel or scaffold compositions and methods of use for cell growth and/or regenerative medicine. The hydrogel comprises a water soluble cellulose compound and, in certain aspects, a fibrous or filamentous matrix. The hydrogels as described provide a support or scaffold that promotes, facilitates, and/or enhances... Agent: New Jersey Institute Of Technology

20110274743 - Medicament for the treatment of pain and inflammation: The use of vitamin D3 for the manufacture of a medicament for the transdermal treatment of neurogenic inflammation and neuropathic pain (including peripheral neuropathic pain); also a method for the relief of neurogenic inflammation and neuropathic pain using this medicament.... Agent: Pharmaceutical Compounding Nz Limited

20110274744 - Process for preparing a surface coated by crosslinked polyelectrolyte multilayer films as a biomimetic reservoir for proteins: The invention relates to processes for coating a surface with a crosslinked polyelectrolytes multilayer film incorporating a protein, preferably a growth factor type protein. The invention also relates to crosslinked polyelectrolytes multilayer films obtained by this process, and a coated surface obtained therefrom.... Agent: Universite Montpellier 2 Sciences Et Techniques

20110274747 - C-terminal fragments of glucagon-like peptide-1 (glp-1): C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.... Agent: The General Hospital Corporation

20110274748 - Cai-based systems and methods for the localized treatment of ocular and other diseases: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for... Agent:

20110274745 - Instillation of liposomal formulation of sirna and antisense oligonucleotides: A pharmaceutically acceptable deliverable composition and methods for administration of macromolecules for sequence-specific gene-silencing in bladder to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), lower urinary tract symptoms (LUTS) locally in the bladder, or other diseases or disorders of the bladder or LUTS, has been discovered. In the... Agent: Lipella Pharmaceuticals Inc.

20110274749 - Methods and compositions for targeting agents into and across the blood-brain barrier and other endothelial cell microvascular barriers: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling... Agent: Bbb Holding B.v.

20110274746 - Therapeutic liposomes and methods for producing and using the same: The present invention provides therapeutic liposomes and methods for producing and using the same. In particular, therapeutic liposomes of the invention comprise phospholipids comprising C16-C22 fatty acid ester moieties. In some embodiments, these therapeutic liposomes are used in assisting delivery of an active compound, e.g., a drug and/or a nutraceutical,... Agent:

20110274750 - Enteric formulation of duloxetine and its core and prepration method: An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the... Agent: Shanghai Zhongxi Pharmaceutical Corporation

20110274753 - Dual release oral tablet compositions of dexlansoprazole: Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.... Agent: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

20110274752 - Modified release pharmaceutical compositions of dexlansoprazole: Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.... Agent: Sanovel Llac Sanayi Ve Ticaret Anonim Sirketi

20110274751 - Trimetazidine formulation with different release profiles: A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled release, while the other layer provides immediate release.... Agent: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

20110274754 - Oral tablet compositions of dexlansoprazole: Oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof having a gradual release and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders.... Agent: Sanovel Llac Sanayi Ve Ticaret Anonim Sirketi

20110274755 - Supportive treatment of liver disease: The invention provides a composition and method for treatment of a subject suffering from liver disease comprising the oral administration of a slow release formulation of diltiazem and thiamine.... Agent:

20110274756 - Method and membrane for tissue regeneration: Tissue regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the... Agent: Geistlich Pharma Ag

20110274759 - Drug loaded polymeric nanoparticles and methods of making and using same: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol.... Agent:

20110274758 - Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind... Agent: Baxter Healthcare S.a.

20110274757 - Nucleic acid delivery vehicle and uses thereof: A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm.... Agent: General Electric Company

20110274760 - Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs: The use of nanoparticles of inorganic materials (e.g., synthetic smectite clays) in ophthalmic and otic pharmaceutical compositions is described. The nanoparticles are utilized as biologically inert carriers or depots for ophthalmic and otic drugs. The nanoparticles may also be utilized to modify the rheological properties of the compositions, so as... Agent:

20110274761 - Polymer carrier: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in... Agent: Polytechnic Institute Of New York University

20110274762 - Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate: The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core.... Agent: Ucb Pharma, S.a.

20110274763 - Slow releasing microcapsules and microspheres containing an active substance: A production method is provided for the preparation of small polymer microcapsules with an oil core and solid microspheres, containing high amounts of biocide by internal phase separation from emulsion droplets with ethyl acetate as a solvent. The size of the microcapsules and microspheres can be controlled with a high... Agent:

20110274764 - Flavored colonic cleansing system: A kit for colonic cleansing includes a phosphate salt laxative, a flavorant, and an oral rehydration mixture. The flavorant includes aspartame and a citrate, and the oral rehydration mixture includes sodium and a glucose containing saccharide. The kit may be used for a colonic cleansing procedure by combining the phosphate... Agent:

20110274765 - Flavored colonic cleansing system: A kit for colonic cleansing includes a phosphate salt laxative, a flavorant, and an oral rehydration mixture. The flavorant includes aspartame and a citrate, and the oral rehydration mixture includes sodium and a glucose containing saccharide. The kit may be used for a colonic cleansing procedure by combining the phosphate... Agent:

20110274766 - Synergy of strong acids and peroxy compounds: Disclosed is a method for improving decontamination in meat, poultry, fish, fruit and vegetable processing using a combination of acid(s) and peroxy compound(s). The method comprises a “stacked” approach, sequentially adding the acid(s) and peroxy compound(s) to an aqueous stream to provide a point-of-use low-pH antimicrobial composition that is highly... Agent:

20110274767 - Production method of titanium oxide sol: There is provided a method for efficiently producing an anatase-type titanium oxide sol in an extremely advantageous dispersion state. The method comprises mixing a titanium alkoxide, an organic acid, and a quaternary ammonium hydroxide with water in a molar ratio of the organic acid of 0.4 to 4.0 relative to... Agent: Nissan Chemical Industries, Ltd.

20110274768 - Antibacterial water treatment agent: An antibacterial water treatment agent constituted by polyethylene containing silver zeolite is characterized in that the silver zeolite has a type-A crystalline structure and is contained by a range of 10 to 30 percent by weight, and that the aforementioned antibacterial water treatment agent is a porous body having continuous... Agent:

20110274769 - Antibacterial melamine product: An antibacterial melamine product includes a main body that is formed by heating and filling molding to have a predetermined shape. The main body includes a substrate portion and an antibacterial agent mixed with the substrate portion. The substrate portion is made of melamine formaldehyde. The antibacterial agent is fused... Agent:

20110274770 - Antiseptic compositions and methods: A skin antisepsis composition comprising a comprising a (C1-4)alcohol and water in a ratio of at least 60:40, a hydroxycarboxylic acid, a cationic film-forming polymer, and at least one antimicrobial agent; and methods of using the composition are provided.... Agent: 3m Innovative Properties Company

20110274771 - Prenatal syptomatic kit: A medication kit includes a plurality of individual non-prophylactic, non-urgent care symptomatic treatments configured to treat the symptoms of a pre-existing medical condition such as pregnancy. The treatments include a combination of pharmaceutical treatments and non-pharmaceutical treatments corresponding to particular symptoms often associated with the pre-existing condition. Each of the... Agent:

20110274772 - Ointment for the topical treatment of haemorrhoids: The present invention provides an ointment comprising aqueous extract of fig leaves, horse chestnut, artichoke leaves and walnut shells, for the treatment of haemorrhoids; a method of manufacturing such an ointment; and the use of fig leaves, artichoke leaves or walnut shells for the manufacture of a medicament for the... Agent:

20110274773 - Copper(i) chloride complex of nicotinic acid and pharmaceutical compositions containing the same: e

20110274774 - System and method for assessing traditional medicines: Methods of defining a standard for a traditional medicine are provided. A method can comprise obtaining at least two samples of the traditional medicine that have been authenticated by qualitative profiling as representing a control positive; quantitatively profiling each of the at least two samples using at least two physicochemical... Agent: Phyto-true, LLC

20110274776 - Compositions comprising extracts of southernwood and an amine compound: The present invention relates to compositions comprising a Southernwood extract and an amine compound, and methods treating skin with said compositions.... Agent:

20110274775 - Extracts of southernwood and topical uses thereof: The present invention relates to a method of treating visibly dry skin. The method includes topically applying a composition comprising a Southernwood extract to said skin.... Agent:

20110274777 - Method for extraction of material from a sapindacea family fruit: The invention of the present application provides a standardized method to obtain a material from Sapindacea family fruits, wherein the material is utilized by itself or in combination with other compounds to make preparations. The material by itself has surfactant, emulsifying and foaming properties, among others. In addition, the invention... Agent:

20110274778 - Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases: The invention relates to the use of a compound comprising D-mannoheptulose and/or perseitol for producing a drug for treating and/or preventing diseases related to the modification of an innate and/or acquired immunity by increasing the production of antimicrobial peptides, preferably hBD-2 without inducing inflammatory reactions, irritation or intolerance. Said compound... Agent: Laboratoires Expanscience

20110268654 - Compositions and methods for delivering a substance to a biological target: The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.... Agent: The General Hospital Corporation

20110268653 - Compositions and methods related to acid stable lipid nanospheres: The present invention relates generally to the fields of chemistry and biochemistry. More particularly, it concerns methods and compositions for the use of fatty asparagine, fatty cysteine, and fatty serine derivatives.... Agent: The Board Of Regents Of The University Of Texas System

20110268655 - Anti-alpha v immunoliposome compositions, methods and uses: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is... Agent:

20110268657 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent:

20110268656 - J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds... Agent:

20110268658 - Polymer-agent conjugates, particles, compositions, and related methods of use: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making... Agent:

20110268659 - High shear application in drug delivery: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an... Agent: H R D Corporation

20110268663 - Intravascular contrast agents: Intravascular contrast agents are provided by Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene. The chelates may be used as an intravascular contrast agent for MRI. Certain embodiments demonstrate enhanced relaxivity and good levels... Agent:

20110268661 - Fluorescent fusion polypeptides and methods of use: Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain... Agent:

20110268662 - Functionalized nanoceria composition for ophthalmic treatment: The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human... Agent:

20110268660 - Method for detecting dysplasia: The present invention provides a method of imaging useful in the determination of sites of dysplasia in patients suffering from Barrett's oesophagus. The method comprises the use of an optical imaging agent comprising a vector which targets the extracellular domain of EGFR, the vector also being selective for EGFR over... Agent:

20110268664 - Composition for addition to drinking water: The invention relates to an effervescent composition for adding to the drinking water of an animal. The composition comprises an effervescent agent and a palatant. The composition may be used in hydration treatment of an animal, as an additive for animal drinking water and for delivering a micronutrient or functional... Agent: Hills Pet Nutrition, Inc

20110268665 - Oil-based foamable carriers and formulations: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses... Agent:

20110268666 - Novel gastroretentive delivery system: A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient.... Agent: Intec Pharma Ltd.

20110268667 - Freshening compositions having a malodor control component and methods thereof: A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor... Agent:

20110268668 - Process for nebulizing aqueous compositions containing highly concentrated insulin: A process for nebulizing highly concentrated solutions of insulin for administration by inhalation.... Agent:

20110268669 - Composition and method for treating eustachian tube dysfunction: A method of treating Eustachian tube dysfunction in a person includes placing the person's body in a position substantially lying on one of the person's left or right sides. The side on which the person is lying is the side affected by Eustachian tube dysfunction. A composition of simethicone in... Agent:

20110268671 - Method of maintaining oral health in animals: Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a diseased caused by oral bacterial in an animal Formula (I); wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or... Agent:

20110268670 - Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.... Agent:

20110268672 - Ferrate(vi)-containing compositions and methods of using ferrate(vi): Compositions containing ferrate(VI) are disclosed. Also, methods are disclosed that utilize ferrate(VI).... Agent: Battelle Memorial Institute

20110268675 - Cosmetic composition using low molecular weight dimethicone: Cosmetic compositions which include low molecular weight non-volatile oils, such as dimethicone, along with silica and a volatile solvent are provided. Such compositions exhibit surprisingly beneficial properties such as long wear, resistance to color transfer, low tack and excellent comfort and shine.... Agent: Revlon Consumer Products Corporation

20110268674 - Polyamide-5 compounds in cosmetic preparations: Polyamide-5 compounds show an increase of the care and/or efficacy properties of cosmetic or dermatological preparations, such as waterproofness, long-term stability, skin moisture and stickiness. The preparations preferably comprise one or more care agents or active ingredients selected from the group of UV filter substances, anti-wrinkle active ingredients, skin moisturizers... Agent: Beiersdorf Ag

20110268676 - Preservatives for cosmetic, toiletry and pharmaceutical compositions: A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to... Agent: Inolex Investment Corporation

20110268673 - Skin treatment: The present invention provides a method for determining the predisposition of an individual to a skin condition comprising identifying the profilaggrin alleles present in the genome of an ex vivo sample taken from the individual. Skin conditions include the ability of an individual to produce Natural Moisturising Factors (NMF), dry... Agent: Conopco, Inc., D/b/a Unilever

20110268679 - Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity... Agent:

20110268677 - Silicone paste compositions: Silicone paste compositions are disclosed by combining a silicone organic elastomer gel with water or a hydrophilic solvent. The silicone paste compositions may further contain a personal or healthcare active. The silicone organic elastomer gel is prepared by reacting in a carrier fluid an organohydrogensiloxane with two polyoxyalkylenes, the first... Agent:

20110268678 - Vitamin d forming sunscreen: A composition suitable for providing protection against ultraviolet radiation containing one or more active ultraviolet radiation absorber through which ultraviolet radiation in approximately the 295 to 315 nanometer range is permitted to enter the skin in an amount sufficient for the body to produce a healthful and disease-opposing quantity of... Agent:

20110268680 - Heat stable protein ingredients: The subject invention pertains to methods of making crosslinked protein-carbohydrate conjugates (CPCCs) and uncrosslinked protein-carbohydrate conjugates (PCCs) that are heat, pH and salt stable. Methods of stabilizing CPCCs and PCCs are also provided. The PCCs and CPCCs formed according to the methods disclosed herein are useful in the food industry... Agent: University Of Tennessee Research Foundation

20110268681 - Method of treating hair: where R1 is an alkyl group having 12 to 50 carbon atoms, R2 is a substituted or un-substituted hydrocarbon group having 1 to about 6 carbon atoms, R3 is 3-aminopropyl group and/or a N-(2-aminoethyl)-3-aminopropyl group, x has a value of 1 to about 2,000, and y has a value of... Agent:

20110268685 - Cosmetic or personal care composition comprising a polymer comprising oxazolidon groups: The invention relates to a cosmetic or personal care composition comprising a polymer which polymer comprises oxazolidon groups. Examples of cosmetic and personal care compositions include hair spray compositions, mousses, gels, lotions, tonics, shampoos, conditioners, rinses, hand and body lotions, facial moisturizers, sunscreens, anti-acne preparations, topical analgesics, mascara's, eyeliners, blush,... Agent: DsmIPAssets B.v.

20110268684 - Hair conditioners comprising imidazolines and ester oils: Cosmetic preparations, in particular hair conditioners, contain at least one imidazoline derivative including at least two long fat groups, and at least two ester oils.... Agent:

20110268683 - Structured suspending systems: A pourable ringing gel surfactant composition comprising a mixture of at least one anionic surfactant having a C8-C18 carbon chain and at least one zwitterionic or amphoteric surfactant having a C8-C18 carbon chain, wherein the ringing gel is capable of suspending solid or liquid particles without sedimentation.... Agent: Rhodia, Inc.

20110268682 - Waving compositions: Disclosed are waving compositions for waving of keratinous fibers, such as hair, containing a) a bisulfite compound, b) a sulfate compound or urea, and c) a lactone or about 0.3% or greater, by weight, of ascorbic acid or a derivative thereof, based on the total weight of the composition and... Agent: L'oreal

20110268686 - Cosmetic composition including an acanthus extract, and use of acanthus in a cosmetic hair-care composition: The present invention relates to a new advantageous utilisation of acanthus in the cosmetic field, and more especially in a haircare composition for creating and/or maintaining the curling effect.... Agent: Pierre Fabre Dermo-cosmetique

20110268687 - Liquid sealant and methods of use: The invention provides a composition useful for forming odor suppressing seals in waterless urinals. Methods of using the composition to form liquid seals as well as waterless urinals employing such liquid seals are further provided.... Agent:

20110268688 - Method and compositions for improving skin and body appearance: A topical composition comprising at least one adipogenesis inhibitor and at least one adipocyte lipolytic agent and, optionally, at least one skin tightening agent; a method for improving the appearance of facial or body skin, treating the appearance of cellulite, or treating the face or body to improve the appearance... Agent:

20110268689 - Photo-crosslinkable antifouling compositions, films obtained from said compositions, and corresponding uses: Photo-crosslinkable antifouling compositions, in particular antibacterial, antifungal and anti-algae ones, which include the combination of at least one telechelic oligoisoprene of a particular formula with an agent for crosslinking the oligoisoprene. The antifouling film is obtained by applying a thin layer of such a liquid composition on a substrate and... Agent: Universite Du Maine

20110268690 - Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same: Compositions comprising poly(hydroxyalkanoates) and agents for use with medical articles are described.... Agent: Advanced Cardiovascular Systems, Inc.

20110268691 - Dsrna delivery composition and methods of use: The present invention provides for compositions comprising a cucurbitacin bait for stimulating insect feeding and a dsRNA—such as for eliciting RNAi mediated gene silencing in an insect. The present invention also provides for methods of delivering a dsRNA molecule to an insect, inhibiting protein expression in an insect, and killing... Agent: Board Of Regents Of The University Of Nebraska

20110268692 - Synergistic rodenticidal compositions: The present invention relates to the combination of an active anticoagulant rodenticidal compound with an analogue of vitamin D, with at least one of the two components being used at a very low concentration.... Agent: Bayer Cropscience Ag

20110268693 - Compounds having crth2 antagonist activity: Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.... Agent: Oxagen Limited

20110268697 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Bristol-myers Squibb Company

20110268694 - Methods for treating vascular leak syndrome: Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells... Agent:

20110268696 - Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22: The present invention relates to use an agent for the prevention and/or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to... Agent: Generon (shanghai) Corporation

20110268695 - Use of hmgb fragments as anti-inflammatory agents: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods... Agent: The General Hospital Corporation

20110268698 - Methods for treating hepatitis c: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IBES activity.... Agent: Ptc Therapeutics, Inc.

20110268699 - Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles: Methods and pharmaceutical compositions for treating multiple sclerosis are described. The methods and pharmaceutical compositions include a therapeutically effective amount of one or more tetracyclic pyrazinoindoles, and/or pharmaceutically acceptable salts thereof.... Agent: Biovista, Inc.

20110268700 - Dosage regimens for hcv combination therapy: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present... Agent: Boehringer Ingelheim International Gmbh

20110268701 - Stress-responsive induction of a therapeutic agent and methods of use: This invention relates to compositions and methods for selective expression of a heterologous nucleic acid sequence in a targeted tissue, and more particularly to the glucose regulated protein 78 (grp78) stress-responsive promoter and its use in gene therapy and the production of transgenic animals.... Agent:

20110268714 - Cd34 stem cell-related methods and compositions: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34− stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34− stem cells used in the instant methods can be genetically modified or... Agent: Apceth Gmbh & Co. Kg

20110268711 - Pancreatic stellate cell specific promoter and uses thereof: There is presently provided a method for effecting pancreatic stellate cell-specific gene expression comprising delivering a nucleic acid comprising a glial fibrillary acidic protein promoter operably linked to a coding sequence to a pancreatic stellate cell.... Agent: Agency For Science, Technology And Research

20110268712 - Stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them: The present invention relates to stem cells suitable for transplantation and to methods for their preparation.... Agent: Yeda Research And Development Co., Ltd.

20110268713 - Variants of ancestral uricases and uses thereof: The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject.... Agent:

20110268702 - Lactobacillus paracasei and weight control: The present invention generally relates to the field of obesity and/or metabolic disorders. In particular the present invention relates to the use of probiotics to treat obesity and/or metabolic disorders. One embodiment of the present invention relates to the use of Lactobacillus paracasei, in particular Lactobacillus paracasei ST11, for the... Agent: Nestec S.a.

20110268704 - Enhanced shelf life and on seed stabilization of liquid bacterium inoculants: The present invention includes a method for producing a liquid inoculant containing a desiccant. The method can improve survival and stability of bacteria in liquid inoculants in pack and on seeds. The method includes providing a liquid inoculant of a bacteria grown to a substantially stationary phase. A desiccant treatment... Agent: Becker Underwood, Inc.

20110268703 - Probiotic strain and antimicrobial peptide derived therefrom: A strain of Enterococcus mundtii has probiotic qualities. The strain of E. mundtii (ST4SA) produces an antimicrobial peptide which exhibits antimicrobial activity against a broad range of bacteria. An isolated nucleotide sequence codes for the antimicrobial peptide (peptide ST4SA). A process is also provided for the production of a peptide... Agent:

20110268715 - Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus: An anti-inflammatory and anti-vaginitis food composition and/or pharmaceutical composition includes Lactobacillus salivarius subsp. salicinius AP-32 (CCTCC stock No. M2011127), Lactobacillus reuteri TE-33(CCTCC stock No. M2011126), Lactobacillus acidophilus F-1 (CCTCC stock No. M2011124), Lactobacillus rhamnosus CT-53 (CCTCC stock No. M2011129) or combinations thereof. The present invention may inhibit TNF-α secretion and... Agent:

20110268705 - Hdac4, hdac5, hdac6, hdac7, and hif1 alpha modulation of retinal cell survival: Methods for inhibiting retinal cell death by altering expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in a retinal cell are provided.... Agent: President And Fellows Of Harvard College

20110268708 - Adipose tissue-derived stem cells for veterinary use: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.... Agent:

20110268707 - Ex-vivo treatment of peripheral blood leukocytes with ifn-lambda: The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ... Agent: Medical Diagnostic Laboratories, LLC

20110268709 - Generation of histocompatible tissues using nuclear transplantation: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.... Agent:

20110268710 - Methods of treating stroke using stem cell-like menstrual blood cells: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for... Agent: Medical College Of Georgia

20110268706 - Preparation method of porous hyaluronic acid sponge for cell delivery system: Provided is a preparation method of a porous hyaluronic acid sponge comprising the steps of: dissolving hyaluronic acid in an aqueous sodium hydroxide solution; adding an epoxy-based crosslinking agent to the resultant aqueous sodium hydroxide solution in which hyaluronic acid is dissolved and homogenizing the hyaluronic acid solution; hydrogelating the... Agent:

20110268716 - Methods for the enrichment of viable foxp3+ cells and uses thereof: The present invention is directed to methods of identifying and enriching for viable Foxp3+ cells and the use of such cells. In particular, the present invention provides methods whereby viable Foxp3+ cells are isolated from a mixed population of cells; Foxp3+ cells being identifiable as those cells with relatively high... Agent: University Of Southern California

20110268718 - Cactus fruit extract: A method for producing a cactus fruit extract for use in formulating a beverage which can be used in the treatment of veisalgia.... Agent: Kaahee Research And Development Gmbh

20110268717 - Herbal-based compositions for alleviating symptoms associated with autism: Aspects of the invention relate to compositions comprising passiflora extracts that may improve neurological and behavioral symptoms associated with Pervasive Developmental Disorders.... Agent:

20110268719 - Annatto extract compositions, including geranyl geraniols and methods of use: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal... Agent: American River Nutrition, Inc.

20110268720 - Formulations of 5-fluorocytosine and uses thereof: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer... Agent: Tocagen Inc.

20110268721 - Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease: The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in... Agent: Amicus Therapeutics, Inc.

20110268723 - Ccr3 inhibition for ocular angiogenesis and macular degeneration: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.... Agent: University Of Kentucky Research Foundation

20110268722 - Combination therapies with mitochondrial-targeted anti-tumor agents: Described are mitochondria-targeted anti-tumor agents, death receptor agonists, autophagy inhibitors, and NF-κB signaling pathway inhibitors, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.... Agent:

20110268724 - Methods and materials relating to cd84-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of... Agent:

20110268725 - Anti-ngf antibodies for the treatment of various disorders: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorder in a patient without having a significant adverse effect on the immune system of the patient.... Agent:

20110268726 - Anti-cd38 human antibodies and uses thereof: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the... Agent:

20110268727 - Anti-interferon-alpha antibodies: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders... Agent: Genentech, Inc.

20110268733 - Anti-siglec-15 antibody: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.... Agent: Daiichi Sankyo Company, Limited

20110268730 - Method for inhibiting bone resorption: The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more... Agent: Amgen Inc.

20110268732 - Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof: The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients... Agent: Thrombologic Aps

20110268731 - Methods of treating autoimmune disorders and/or inflammatory disorders: The present invention relates to dendrimer compositions configured for treating inflammatory disorders and autoimmune disorders, and related methods of synthesis. Specifically, the present invention relates to methods for treating rheumatoid arthritis with PAMAM dendrimers having functional ligands configured for treating rheumatoid arthritis (e.g., therapeutic agents, pro-drugs, targeting agents, trigger agents,... Agent: The Regents Of The University Of Michigan

20110268734 - Preventive or therapeutic agent for psoriatic arthritis comprising il-6 antagonist as active ingredient: A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.... Agent: Chugai Seiyaku Kabushiki Kaisha

20110268728 - Solubility optimization of immunobinders: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of... Agent: Esbatech, An Alcon Biomedical Research Unit LLC

20110268729 - Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist: The invention relates to methods for the treatment or prophylaxis of amyotrophic lateral sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of a Nogo-A antagonist.... Agent:

20110268737 - Hla-g proteins and pharmaceutical uses thereof: The present invention relates to novel proteins and pharmaceutical uses thereof. The invention more specifically relates to novel fusion proteins comprising a domain of an HLA-G antigen fused to an Fc domain of an immunoglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same,... Agent: Hla-g Technologies

20110268736 - Method for treating congenital myopathy: The invention relates to methods and compositions for therapy for congenital myopathies.... Agent: Children's Medical Center Corporation

20110268735 - Multimeric constructs: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular... Agent:

20110268738 - Antibodies against hmgb1 and fragments thereof: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to particular fragments of HMGB1, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade, methods of detecting and/or identifying an agent that binds to an HMGB1 polypeptide... Agent:

20110268740 - Fully human influenza m2 specific antibodies: The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for... Agent: Intercell Ag

20110268739 - Human binding molecules having killing activity against enterococci and uses thereof: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis,... Agent: Crucell Holland B.v.

20110268741 - Immunotherapy for contact dermatitis using co-signal regulation: Compounds, compositions and methods for immunotherapy in contact dermatitis. Compounds and compositions (e.g. monoclonal antibodies) that stimulate the LAIR-1 expression pathway in LAIR-1 expressing immune cells and are useful for preventing or treating contact dermatitis are provided.... Agent: The Johns Hopkins University

20110268742 - Pctp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP),... Agent: Galderma Research & Development

20110268743 - Probiotics, secretory iga and inflammation: The present invention relates generally to the field of nutrition, health and wellness. In particular the present invention relates to probiotics and ways to increase their effectiveness. One embodiment of the present invention relates to a combination of probiotics with SIgA and possible uses of this combination. For example a... Agent: Nestec S.a.

20110268745 - Antibodies against tissue factor pathway inhibitor (tfpi): The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.... Agent: Novo Nordisk A/s

20110268744 - Method of diagnosis of infection by mycobacteria and reagents therefor: The present invention provides isolated M. tuberculosis protein that is a putative Ketol-acid reductoisomerase (KARI; SEQ ID NO: 1) and immunogenic peptide fragments thereof, and antibodies produced against the full-length protein and immunogenic peptide fragments for the diagnosis of tuberculosis and/or infection by one or more mycobacteria of the M.... Agent:

20110268746 - Human cytomegalovirus neutralizing antibodies and use thereof: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes... Agent: Institute For Research In Biomedicine

20110268748 - Nurr-1 interacting protein (nuip): Provided herein are methods of promoting the activity of Nurr1 in a cell comprising contacting the cell with NuIP or an analog or fragment thereof. Also provided are methods of treating or preventing a condition associated with reduced dopaminergic function in a subject, comprising administering to the subject NuIP or... Agent: The University Of Rochester

20110268747 - Stxbp1 as psychiatric biomarker in murine model system and their uses: A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro... Agent:

20110268749 - Treatment of cancer via targeting of il-13 receptor-alpha2: Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13Rα2 antagonist, and/or a AP-I antagonist.... Agent: The Government Of The US As Represented By The Secretary Department Of Health And Human Services

20110268750 - Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions: The present invention also concerns exploiting the properties of exosomes comprising a polypeptide of the invention and of immunogenic compositions of the invention for the prophylaxis and/or treatment of an infection by a pathogenic agent, a pathogenic organism, a tumour antigen or a cytoplasmic antigen, in particular to elicit or... Agent: Centre National De La Recherche Scientifique

20110268751 - Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30... Agent: Seattle Genetics, Inc.

20110268754 - Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services

20110268752 - Inducible regulatory t-cell generation for hematopoietic transplants: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a... Agent: Regents Of The University Of Minnesota

20110268753 - Process for regulating immune response: The discovery of FcγRIIc expression on B-cells allows several new methods of prediction or regulation of immune responses. A process of altering an immune response in a subject is provided by altering the expression level or activity of FcγRIIc on a cell. The relative ratio of activating FcγRIIc to inhibitory... Agent: The Uab Research Foundation

20110268756 - Modified amyloid beta peptide: An object of the invention is to provide a peptide based on a sequence of an amyloid β peptide that may allow for induction of enhanced immune response and is safe and efficacious for prophylaxis and treatment of Alzheimer disease. An amyloid β peptide or a portion thereof with addition... Agent: The Chemo-sero-therapeutic Research Institute

20110268755 - Survivin peptides for autoimmune therapies: Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino... Agent: Health Research Inc.

20110268758 - Tuberculosis antigen detection assays and vaccines: The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules,... Agent:

20110268757 - Use of phenol-soluble modulins for vaccine development: The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSMα, PSMγ and PSMδ peptides to an antigen (from a pathogen or a tumor associated protein) increases the... Agent: Proyecto De Biomedicina Cima, S.l.

20110268759 - Novel anti-stretch mark active agent, and compositions containing same: The invention relates to a method for the cosmetic prevention and/or treatment of stretch marks on the skin, characterised in that the method comprises administering a composition containing arabinogalactan as an active principle to a person that may develop or has stretch marks. Said cosmetic composition can be administered in... Agent: Laboratoires Expanscience

20110268760 - Salmonella vectored vaccines against chlamydia and methods of use: The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated Salmonella vaccine vector comprises aroC and ssaV attenuating mutations. The heterologous polynucleotides encoding the immunogenic Chlamydial peptides can be under the control of an inducible promoter... Agent: Emergent Product Development Uk Limited

20110268761 - Effective sensitizing dose of a gelled immunomodulating topical composition: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.... Agent: Hapten Pharmaceuticals, LLC

20110268762 - Immunization of avians by mucosal administration of non-replicating vectored vaccines: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes... Agent:

20110268763 - Polynucleotides that stimulate neutrophils: The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attributes to successfully establishing a nidus of infection. They also stimulate neutrophil functions. Accordingly, the nucleotides,... Agent: Immunom Technologies, Inc.

20110268764 - Immune response inducing preparations: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.... Agent: Avir Green Hills Biotechnology Research Development Trade Ag

20110268765 - Injectable botulinum toxin formulations: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized... Agent: Revance Therapeutics, Inc.

20110268766 - Engineered cells expressing multiple immunomodulators and uses thereof: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in... Agent: Intrexon Corporation

20110268767 - Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses: Novel antigen-presenting cells, including but not limited to dendritic cells, that are loaded with antigens from dead or dying cells including allogenic cell lines, and the methods for making such antigen-presenting cells are described. These loaded antigen-presenting cells induce therapeutic immune responses in humans. Such loaded antigen-presenting cells are useful... Agent: Baylor Research Institute

20110268774 - preparation of stem cells with reprogrammed cell signalling, a method of producing the preparation and a method of use thereof: The invention is applied in the therapy of brain and spinal cord tumors, degenerative, hypoxic, ischemic diseases and traumatic injuries of the central nervous system (CNS) and other diseases of humans and animals. Object of invention is to provide target delivery of signaling substance to the pathological area of an... Agent:

20110268770 - Chewable gelled emulsions: An oral pharmaceutical composition in unit dose form, each unit dose comprising a statin within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion, one or both of the oil phase and the water phase whereof comprises a physiologically tolerable omega-3 acid ester.... Agent: Probio Asa

20110268771 - Chewable gelled emulsions: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.... Agent: Probio Asa

20110268768 - Compositions and methods for treating atherosclerosis: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis... Agent: Queen's University At Kingston

20110268769 - Drug delivery vehicle for cancer therapy, process for producing the same, and pharmaceutical preparation using the same: The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral... Agent:

20110268773 - Inclusion bodies, bacterial cells and compositions containing them and uses thereof: The present invention relates to an isolated inclusion body comprising a polypeptide, characterised in that such inclusion body is in particulate form. The present invention also refers to a bacterial cell comprising said inclusion body. The present invention additionally refers to a composition comprising said inclusion body and a eukaryotic... Agent: Consejo Superior De Investigaciones Cient&#xcd Ficas

20110268775 - Nanoparticle pharmaceutical formulations: The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare... Agent: Pharmanova, Inc.

20110268772 - Pharmaceutical composition containing an anionic drug and a production method thereof: Disclosed are an anionic drug-containing pharmaceutical composition comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a... Agent: Samyang Corporation

20110268776 - Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration: A biologically engineered construct comprising of a polymeric biomatrix, designed with a nanophase texture, and a therapeutic agent for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent may... Agent:

20110268778 - Delivery particles: The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional... Agent:

20110268779 - Gum compositions: A chewing gum composition comprising porous silicon is described.... Agent:

20110268777 - Lotion composition for wet wipes: A lotion composition for a skin cleaning wipe comprises a superwetter and a rheology modifier, adapted to provide an enhanced sensation of wetness with a reduced quantity of liquid. Complementary emollients, emulsifiers, and adjuncts and a method for increasing the wetness perception of a wet wipe are also described.... Agent:

20110268780 - Solid core microcapsular compositions and uses thereof: Provided are microcapsules containing a solid core including at least one essential oil mixed with a porous solid material, where this solid core is coated by at least one layer of a polyurea film and/or a polyurethane film or an amphipathic shell composed of a multivalent salt form of at... Agent: Botanocap Ltd.

20110268781 - Drug eluting composite: The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.... Agent: Gore Enterprise Holdings, Inc.

20110268782 - Polyurethanes for osteoimplants: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an... Agent: Warsaw Orthopedic, Inc.

20110268783 - Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery: A partially microcellular, selectively hydrophilic composite as a self-standing construct or a component of a device for ocular delivery of at least one bioactive agent, the composite comprising a highly hydrophilic microcellular foam adjoined with a flexible hydrophobic barrier polymeric film.... Agent: Poly-med, Inc.

20110268784 - Clay-based hemostatic agents and devices for the delivery thereof: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate.... Agent:

20110268785 - Propynylaminoindan transdermal compositions: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing... Agent:

20110268786 - Patch production technology: The invention relates to a transdermal, especially dopaminergic patch, comprising a release liner film, an active substance layer, and a carrier film, wherein the active substance layer is applied between the release liner film and the carrier film. The release liner film and/or the carrier film thereby comprise at least... Agent: Ucb Pharma Gmbh

20110268788 - Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis: The present invention relates to the use of an immunotherapeutic agent having cell wall fragments of a virulent strain of Mycobacterium tuberculosis for the preparation of a drug suitable for the primary prophylaxis of tuberculosis. The immunotherapeutic agent is capable of inducing a protective response that is more effective than... Agent: Archivel Farma, S.l.

20110268787 - Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof: The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.... Agent:

20110268791 - Porous nanoparticle supported lipid bilayer nanostructures: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components,... Agent:

20110268790 - Snake factor v and methods of use thereof as a procoagulant: Compositions and Methods for the treatment of coagulation disorders using Factor V variants are provided. Preferred disorders include hemophilia A and B.... Agent:

20110268789 - Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents: This invention relates to methods and compositions for the treatment, management or prevention of injuries to one or more of the organs of the body, such as the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of humans or other mammals caused by one or more anticancer agents. The methods... Agent:

20110268792 - Surface active proteins as excipients in solid pharmaceutical formulations: The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical... Agent: Basf Se

20110268793 - Kits and methods for nutrition supplementation: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids... Agent:

20110268794 - Methods and materials for delivering bile acids: This document relates to methods and materials for administering bile acid compounds to treat conditions associated with constipation. For example, formulations designed for the delayed-release of a bile acid compound (e.g., sodium chenodeoxycholate) to treat constipation are provided.... Agent:

20110268795 - Compositions and methods for inducing satiety and treating non-insulin dependent diabetes mellitus, prediabetic symptoms, insulin resistance and related disease states and conditions: The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a... Agent:

20110268796 - Pharmaceutical formulations useful in the treatment of insomnia: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable... Agent: Orexo Ab

20110268797 - Multicoated aliskiren formulations: An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers.... Agent: Sanovel Iiac Sanayi Ve Ticaret Anonim Sirketi

20110268799 - Oral controlled release dosage form: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.... Agent: Andrx Pharmaceuticals, Inc.

20110268798 - Orally disntegrating tablets for the treatment of pain: An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients.... Agent: Add Advanced Drug Delivery Technologies Ltd

20110268801 - Novel compounds and compositions and methods of use: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Ardea Biosciences, Inc.

20110268800 - Unsaturated fatty acids as thrombin inhibitors: A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the unsaturated fatty acid as a free fatty acid or a fatty acid radical of a... Agent: Lts Lohmann Therapie-systeme Ag

20110268805 - Adjuvant incorporation in immunonanotherapeutics: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments,... Agent:

20110268802 - Delivery particle: The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional... Agent:

20110268803 - Lung targeting dual drug delivery system: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage... Agent: The Trustees Of Princeton University

20110268804 - Targeting of antigen presenting cells with immunonanotherapeutics: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen... Agent: The Brigham And Women's Hospital, Inc.

20110268806 - Antisolvent solidification process: The present invention relates to a antisolvent solidification process wherein a liquid medium comprising at least one organic or inorganic compound which is to be solidified is forced through a membrane into one or more antisolvents, or wherein one or more antisolvents are forced through a membrane into a liquid... Agent: Organon Usa, Inc.

20110268807 - Biodegradable microspheres and methods of use thereof: The present invention provides biodegradable microspheres, compositions comprising a subject biodegradable microsphere, and methods of using a subject biodegradable microsphere for delivery of an agent to a site in an individual.... Agent:

20110268808 - Dual-release pharmaceutical suspension: Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended... Agent: Panacea Biotec Ltd.

20110268809 - Nicotine-containing pharmaceutical compositions: A composition intended to be employed for therapeutic purposes incorporates a source of nicotine and at least one levulinate moiety. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The levulinate moiety can... Agent:

20110268810 - Polymeric materials loaded with mutagenic and recombinagenic nucleic acids: Polymeric microparticles are used to deliver recombinagenic or mutagenic nucleic acid molecules such as donor nucleic acid alone, or in combination with triplex-forming molecules, to induce a site-specific mutation in the target DNA. Target cells endocytose the particles, releasing the nucleic acid molecules inside of the cell, where they induce... Agent: Yale University

20110268811 - Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including... Agent: U.s. Nutraceuticals, LLC D/b/a Valensa International

20110268812 - Cosmetic or dermatological composition comprising the combination of honey and a peptide: A cosmetic composition has a combination of honey or royal jelly, and a peptide, including at least the amino acid sequence Gly-X1-X2-Pro-Gly. Applying the composition makes it possible to delay the appearance of the signs of skin aging or to slow down the effects thereof.... Agent: Lvmh Recherche

20110268813 - Preventing liver injury and improving liver function effects of ena-actimineral resources: Disclosed is a composition with anti-oxidative, anti-aging and liver-function improvement activities containing ENA actimineral resource A activated water. More specifically, disclosed are a pharmaceutical composition and a health food or health supplement containing, as an active ingredient, an alkaline ENA actimineral resource A activated water prepared from Sepia bone and... Agent:

20110268814 - Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease: The present invention provides a method for treatment of acute cerebrovascular diseases, and also provides the use of the extracts from rabbit skin inflamed by vaccinia virus in the manufacture of a medicament for treatment of acute cerebrovascular diseases.... Agent: Vanworld Pharmaceutical (rugao) Co., Ltd.

20110268815 - Temperature-insensitive calcium phosphate cements: Temperature-insensitive calcium phosphate cements and methods of using the same are provided. Aspects of the cements include a dry component having fine and coarse calcium phosphate particulate reactants and a setting fluid which includes a cellulose. The dry component and setting fluid may be combined over a broad temperature range... Agent:

20110268816 - Apparatuses and systems to process a fluid, and methods for using the same: A method for oxygenating a fluid, the method including launching a sub-orbital lower-level apparatus to a predetermined altitude greater than 20,000 feet above sea level. The method also includes, at the predetermined altitude, actuating a fluid capture mechanism sealingly configured to collect and store an atmospheric fluid. In addition, returning... Agent:

20110268817 - Compounds useful for the prevention or treatment of accomodative asthenopia: It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20110268818 - Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload: The invention provides compositions comprising a lipocalin, such as NGAL, and a mammalian siderophore that are useful as iron chelators and iron donors. The invention also provides mammalian siderophore compounds of Formula (I): The invention further provides, methods of treatment and methods of diagnosis.... Agent:

20110268819 - Antinfective free intramammary veterinary composition: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.... Agent: Bimeda Research & Development Limited

20110268820 - Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue: Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be... Agent:

20110268821 - Extracting an extract substance from a raw material: The present invention relates broadly to the extraction of an extract substance from a raw material. The extract substance may have application in the food, cosmetics, insecticide or other industries. The raw material may be in the form of vegetable or fruit matter or waste. The extract substance is to... Agent: Ddf (australia) Pty Ltd

20110268822 - Methods for synthesizing kotalanol and stereoisomers and analogues thereof, and novel compounds produced thereby: Compounds having the general formula (I): wherein X is S, Se or NH, and stereoisomers thereof, and de-O-sulfonated analogues of all of the foregoing, but excluding naturally occurring kotalanol and de-O-sulfonated kotalanol, and methods for synthesizing same. The compounds are useful as glycosidase inhibitors, and may be used in the... Agent: Simon Fraser University

20110268824 - Composition for preventing or treating artherosclerosis: A composition according to the present invention is a composition containing extract of Panax ginseng C.A. Meyer fruit as an active ingredient for preventing or treating artherosclerosis. The extract is confirmed to effectively suppress lesions or generation of a vascular inflammation factor caused by artherosclerosis. Thus, the composition is suitable... Agent: Amorepacific Corporation

20110268823 - Method for preparing extract fracton reinforced with ginsenosides rg1 or rb1 from ginseng: The present invention provides a method for preparing an extract fraction reinforced with ginsenoside Rg1 or Rb1 from ginseng. The method for preparing an extract fraction reinforced with ginsenoside Rg1 comprises the steps of: concentrating an alcohol extract of ginseng and then adsorbing the extract diluted in water by adding... Agent:

20110268825 - Compositions that include anthocyanidins and methods of use: The compositions described herein and featured in the present invention include those that comprise anthocyanidin combinations rich in delphinidins, including delphinidins such as the ones found in berries. The compositions can optionally include either compositions that comprise andrographolides, such as the ones found in a plant of the genus Andrographis,... Agent:

20110268826 - Gip-increase inhibitor: A GIP-increase inhibitor, which is useful as a drug or a food, comprising a rice bran extract as an active ingredient.... Agent: Kao Corporation

20110268827 - Eyesight-protecting composition containing functional components having preventive and therapeutic efficacy in diabetes or diabetes complications: A vision-protecting composition with prophylactic and therapeutic activity of diabetes or diabetic complications, comprising calcium, vitamin A, vitamin B, vitamin C and vitamin D as functional ingredients, in combination with at least one herb extract selected from the group consisting of a wolfberry extract, an Astragalus membranaceus extract, a Senna... Agent:

20110268828 - Cell receptor blocker for preventing and treating avian influenza and other diseases caused by viruses: Use of previously inactivated viral particles of the avian influenza virus or of previously purified antigenic components thereof, alone or in combination with carriers of biological origin in a composition administered via the respiratory system in order to prevent and to treat avian influenza, and also the composition mentioned. The... Agent:

20110268829 - Quality of life for hepatitis c patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and n-acetyl d-glucosamine: Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a... Agent: